Document:

Registration Rights Agreement, dated October 13, 2010.

  
 EXHIBIT 10.5

 REGISTRATION RIGHTS AGREEMENT 
 This Registration Rights Agreement (the “Agreement”) is made and entered into as of October 13, 2010, by and among World Heart Corporation, a Delaware corporation (the “Company”),
and the several purchasers signatory hereto (each an “Investor” and collectively, the “Investors”). 
 This
Agreement is made pursuant to the Securities Purchase Agreement, dated as of October 13, 2010, between the Company and each Purchaser (the “Purchase Agreement”). 

The parties hereby agree as follows: 
 1. Certain Definitions. 
 As used in this Agreement, the following
terms shall have the following meanings: 
 “Business Day” means any day other than a Saturday, Sunday or other
day on which commercial banks are authorized to close under the applicable laws of, or are in fact closed in, the State of New York. 
 “Common Stock” means the Company’s Common Stock, par value $0.001 per share, and any securities into which such shares may hereinafter be reclassified. 

“Filing Deadline” means, with respect to the Registration Statement required to be filed pursuant to Section 2(a),
the 30th calendar day following the Closing Date, provided, however, that if the Filing Deadline falls on a Saturday, Sunday or other day that the Commission is closed for business, the Filing Deadline shall be extended to the next business day on
which the Commission is open for business. 
 “Investors” means, unless the context otherwise indicates, the
parties listed on the signature pages hereto as “Investors” and any Affiliate or permitted transferee of any of them who is a subsequent holder of the Registrable Securities. 

“Liquidated Damages Amount” of each Investor is $.001 multiplied by the number of Registrable Securities held by such
Investor from time to time. 
 “Prospectus” means (i) the prospectus included in any Registration
Statement, as amended or supplemented by any prospectus supplement, with respect to the terms of the offering of any portion of the Registrable Securities covered by such Registration Statement and by all other amendments and supplements to the
prospectus, including post-effective amendments and all material incorporated by reference in such prospectus, and (ii) any “free writing prospectus” as defined in Rule 405 under the 1933 Act. 

“Register,” “registered” and “registration” refer to a registration made by preparing
and filing a Registration Statement or similar document in compliance with the 1933 Act (as defined below), and the declaration or ordering of effectiveness of such Registration Statement or document. 

  
 “Registrable
Securities” means (i) the shares of Common Stock acquired by the Investors pursuant to the Purchase Agreement and (ii) any other securities issued or issuable with respect to or in exchange for Registrable Securities; provided,
that, a security shall cease to be a Registrable Security upon (A) sale pursuant to a Registration Statement or Rule 144 under the 1933 Act, or (B) such security becoming eligible for sale without notice or restriction (including without
limitation any restriction relating to the availability of current public information about the Company and any volume restrictions) by the Investors pursuant to Rule 144. 
 “Registration Statement” means any registration statement of the Company filed under the 1933 Act that covers the resale of any of the Registrable Securities pursuant to the provisions of
this Agreement, amendments and supplements to such Registration Statement, including post-effective amendments, all exhibits and all material incorporated by reference in such Registration Statement. 

“Required Investors” means (i) each Investor holding 20% or more of the Registrable Securities and (ii) the
Investors holding a majority of the Registrable Securities. 
 “SEC” means the U.S. Securities and Exchange
Commission. 
 “1933 Act” means the Securities Act of 1933, as amended, and the rules and regulations
promulgated thereunder. 
 “1934 Act” means the Securities Exchange Act of 1934, as amended, and the rules and
regulations promulgated thereunder. 
 2. Registration. 

(a) Registration Statements. 
 (i) Promptly following the closing of the purchase and sale of the securities contemplated by the Purchase Agreement (the “Closing Date”) but no later than Filing Deadline, the Company
shall prepare and file with the SEC one Registration Statement on Form S-3 (or, if the Company is not then eligible to use Form S-3 to register the resale of the Registrable Securities, on such form of registration statement as is then available to
effect a registration for resale of the Registrable Securities), covering the resale of the Registrable Securities. Subject to any SEC comments, such Registration Statement shall include the plan of distribution attached hereto as Exhibit
A; provided, however, that no Investor shall be named as an “underwriter” in the Registration Statement without the Investor’s prior written consent. Such Registration Statement also shall cover, to the extent allowable under
the 1933 Act and the rules promulgated thereunder (including Rule 416), such indeterminate number of additional shares of Common Stock resulting from stock splits, stock dividends or similar transactions with respect to the Registrable
Securities. Such Registration Statement shall not include any shares of Common Stock or other securities for the account of any holder other than the Investors without the prior written consent of the Required Investors. The Registration
Statement (and each amendment or supplement thereto, and each request for acceleration of effectiveness thereof) shall be provided in accordance with Section 3(c) to the Investors and their counsel prior to its filing or other
submission. If a Registration Statement covering the Registrable Securities is not filed with the SEC on or prior to the Filing Deadline, the Company will make payments to each Investor, as liquidated damages and not as a penalty, in an amount
equal to such Investor’s Liquidated Damages Amount for each 30-day period (or pro rata for any portion thereof) following the Filing Deadline for which no Registration Statement is filed with respect to such Registrable Securities. The amounts
payable as liquidated damages pursuant to this paragraph shall be paid monthly within three (3) Business Days of the last day of each 30-day period following the Filing Deadline. Such payments shall constitute the Investors’ exclusive
monetary remedy for such events, but shall not affect the right of the Investors to seek injunctive relief. Such payments shall be made to each Investor in cash. 

  

(b) Expenses. The Company will pay all expenses associated with each registration, including filing and printing fees,
the Company’s counsel and accounting fees and expenses, costs associated with clearing the Registrable Securities for sale under applicable state securities laws, listing fees, reasonable fees and expenses of counsel to the Investors not to
exceed $25,000 in the aggregate, and the Investors’ reasonable expenses in connection with the registration, but excluding discounts, commissions, fees of underwriters, selling brokers, dealer managers or similar securities industry
professionals with respect to the Registrable Securities being sold. 
 (c) Effectiveness. 

(i) The Company shall use commercially reasonable best efforts to have the Registration Statement declared effective as soon as
practicable. The Company shall notify the Investors by facsimile or e-mail as promptly as practicable, and in any event, within twenty-four (24) hours, after any Registration Statement is declared effective and shall simultaneously provide
the Investors with copies of any related Prospectus to be used in connection with the sale or other disposition of the securities covered thereby. If (A)(x) a Registration Statement covering the Registrable Securities is not declared effective
by the SEC prior to the earliest of (i) five (5) Business Days after the SEC shall have informed the Company that no review of the Registration Statement will be made or that the SEC has no further comments on the Registration Statement or
(ii) the 90th day after the Filing Deadline, or (B) after a Registration Statement has been declared effective by the SEC, sales cannot be made pursuant to such Registration Statement for any reason (including without limitation by
reason of a stop order, or the Company’s failure to update the Registration Statement), but excluding any Allowed Delay (as defined below) or the inability of any Investor to sell the Registrable Securities covered thereby due to market
conditions, then the Company will make payments to each Investor, as liquidated damages and not as a penalty, in an amount equal to such Investor’s Liquidated Damages Amount for each 30-day period (or pro rata for any portion thereof) following
the date by which such Registration Statement should have been effective (the “Blackout Period”). Such payments shall constitute the Investors’ exclusive monetary remedy for such events, but shall not affect the right of the
Investors to seek injunctive relief. The amounts payable as liquidated damages pursuant to this paragraph shall be paid monthly within three (3) Business Days of the last day of each 30-day period following the commencement of the Blackout
Period until the termination of the Blackout Period. Such payments shall be made to each Investor in cash. 

  
 (ii) For not
more than twenty (20) consecutive days, and for not more than an aggregate of forty-five (45) days in any twelve (12) month period, the Company may suspend the use of any Prospectus included in any Registration Statement contemplated
by this Section in the event that the Company determines in good faith that such suspension is necessary (A) to delay the disclosure of material non-public information concerning the Company, the disclosure of which at the time would be, in the
good faith opinion of the Company, materially detrimental to the Company or (B) to amend or supplement the affected Registration Statement or the related Prospectus so that such Registration Statement or Prospectus shall not include an untrue
statement of a material fact or omit to state a material fact required to be stated therein or necessary to make the statements therein, in the case of the Prospectus in light of the circumstances under which they were made, not misleading (an
“Allowed Delay”); provided, that the Company shall promptly (a) notify each Investor in writing of the commencement of and the reasons for an Allowed Delay, but shall not (without the prior written consent of an Investor) disclose to
such Investor any material non-public information giving rise to an Allowed Delay, (b) advise the Investors in writing to cease all sales under the Registration Statement until the end of the Allowed Delay and (c) use commercially
reasonable best efforts to terminate an Allowed Delay as promptly as practicable. 
 (d) Rule 415; Cutback If
at any time the SEC takes the position that the offering of some or all of the Registrable Securities in a Registration Statement is not eligible to be made on a delayed or continuous basis under the provisions of Rule 415 under the 1933 Act or
requires any Investor to be named as an “underwriter”, the Company shall use its commercially reasonable best efforts to persuade the SEC that the offering contemplated by the Registration Statement is a valid secondary offering and not an
offering “by or on behalf of the issuer” as defined in Rule 415 and that none of the Investors is an “underwriter”. The Investors shall have the right to participate or have their counsel participate in any meetings or
discussions with the SEC regarding the SEC’s position and to comment or have their counsel comment on any written submission made to the SEC with respect thereto. No such written submission shall be made to the SEC to which the
Investors’ counsel reasonably objects. In the event that, despite the Company’s commercially reasonable best efforts and compliance with the terms of this Section 2(d), the SEC refuses to alter its position, the Company shall
(i) remove from the Registration Statement such portion of the Registrable Securities (the “Cut Back Shares”) and/or (ii) agree to such restrictions and limitations on the registration and resale of the Registrable Securities as
the SEC may require to assure the Company’s compliance with the requirements of Rule 415 (collectively, the “SEC Restrictions”); provided, however, that the Company shall not agree to name any Investor as an “underwriter” in
such Registration Statement without the prior written consent of such Investor. Any cut-back imposed on the Investors pursuant to this Section 2(d) shall be allocated among the Investors on a pro rata basis, unless the SEC Restrictions
otherwise require or provide. No liquidated damages shall accrue as to any Cut Back Shares until such date as the Company is able to effect the registration of such Cut Back Shares in accordance with any SEC Restrictions (such date, the
“Restriction Termination Date” of such Cut Back Shares). From and after the Restriction Termination Date applicable to any Cut Back Shares, all of the provisions of this Section 2 (including the liquidated damages provisions)
shall again be applicable to such Cut Back Shares; provided, however, that (i) the Filing Deadline for the Registration Statement including such Cut Back Shares shall be ten (10) Business Days after such Restriction Termination Date, and
(ii) the date by which the Company is required to obtain effectiveness with respect to such Cut Back Shares under Section 2(c) shall be tolled for a period equal to the number of days elapsed from the date the Registration Statement
initially including such Cut Back Shares was first filed with the SEC and the Restriction Termination Date applicable to such Cut Back Shares. 

  
 (e) Right to
Piggyback Registration. 
 (i) If at any time following the date of this Agreement that any Registrable Securities
remain outstanding (A) there is not one or more effective Registration Statements covering all of the Registrable Securities and (B) the Company proposes for any reason to register any shares of Common Stock under the 1933 Act (other than
pursuant to a registration statement on Form S-4 or Form S-8 (or a similar or successor form)) with respect to an offering of Common Stock by the Company for its own account or for the account of any of its stockholders, it shall at each such time
promptly give written notice to the holders of the Registrable Securities of its intention to do so (but in no event less than thirty (30) days before the anticipated filing date) and, to the extent permitted under the provisions of Rule 415
under the 1933 Act, include in such registration all Registrable Securities with respect to which the Company has received written requests for inclusion therein within fifteen (15) days after receipt of the Company’s notice (a
“Piggyback Registration”). Such notice shall offer the holders of the Registrable Securities the opportunity to register such number of shares of Registrable Securities as each such holder may request and shall indicate the intended
method of distribution of such Registrable Securities. 
 (ii) Notwithstanding the foregoing, (A) if such
registration involves an underwritten public offering, the Investors must sell their Registrable Securities to, if applicable, the underwriter(s) at the same price and subject to the same underwriting discounts and commissions that apply to the
other securities sold in such offering (it being acknowledged that the Company shall be responsible for other expenses as set forth in Section 2(b)) and subject to the Investors entering into customary underwriting documentation for selling
stockholders in an underwritten public offering, and (B) if, at any time after giving written notice of its intention to register any Registrable Securities pursuant to Section 2(e)(i) and prior to the effective date of the registration
statement filed in connection with such registration, the Company shall determine for any reason not to cause such registration statement to become effective under the 1933 Act, the Company shall deliver written notice to the Investors and,
thereupon, shall be relieved of its obligation to register any Registrable Securities in connection with such registration; provided, however, that nothing contained in this Section 2(e)(ii) shall limit the Company’s liabilities and/or
obligations under this Agreement, including, without limitation, the obligation to pay liquidated damages under this Section 2. 
 3. Company Obligations. The Company will use commercially reasonable best efforts to effect the registration of the Registrable Securities in accordance with the terms hereof, and
pursuant thereto the Company will, as expeditiously as possible: 
 (a) use commercially reasonable best efforts to cause
such Registration Statement to become effective and to remain continuously effective for a period that will terminate upon the earlier of (i) the date on which all Registrable Securities covered by such Registration Statement as amended from
time to time, have been sold, and (ii) the date on which all Registrable Securities covered by such Registration Statement may be sold without notice or restriction pursuant to Rule 144, including, without limitation, any restriction relating
to the availability of current public information about the Company and any volume restrictions (the “Effectiveness Period”), and advise the Investors in writing when the Effectiveness Period has expired; 

  
 (b) prepare and
file with the SEC such amendments and post-effective amendments to the Registration Statement and the Prospectus as may be necessary to keep the Registration Statement effective for the Effectiveness Period and to comply with the provisions of the
1933 Act and the 1934 Act with respect to the distribution of all of the Registrable Securities covered thereby; 

(c) provide copies to and permit counsel designated by the Investors to review each Registration Statement and all amendments and
supplements thereto no fewer than seven (7) days prior to their filing with the SEC and not file any document to which such counsel reasonably objects; 
 (d) furnish to the Investors and their legal counsel (i) promptly after the same is prepared and publicly distributed, filed with the SEC, or received by the Company (but not later than two
(2) Business Days after the filing date, receipt date or sending date, as the case may be) one (1) copy of any Registration Statement and any amendment thereto, each preliminary prospectus and Prospectus and each amendment or supplement
thereto, and each letter written by or on behalf of the Company to the SEC or the staff of the SEC, and each item of correspondence from the SEC or the staff of the SEC, in each case relating to such Registration Statement (other than any portion of
any thereof which contains information for which the Company has sought confidential treatment), and (ii) such number of copies of a Prospectus, including a preliminary prospectus, and all amendments and supplements thereto and such other
documents as each Investor may reasonably request in order to facilitate the disposition of the Registrable Securities owned by such Investor that are covered by the related Registration Statement; 

(e) use commercially reasonable best efforts to (i) prevent the issuance of any stop order or other suspension of
effectiveness and, (ii) if such order is issued, obtain the withdrawal of any such order at the earliest possible moment; 

(f) prior to any public offering of Registrable Securities, use commercially reasonable best efforts to register or qualify or
cooperate with the Investors and their counsel in connection with the registration or qualification of such Registrable Securities for offer and sale under the securities or blue sky laws of such jurisdictions requested by the Investors and do any
and all other commercially reasonable acts or things necessary or advisable to enable the distribution in such jurisdictions of the Registrable Securities covered by the Registration Statement; provided, however, that the Company shall not be
required in connection therewith or as a condition thereto to (i) qualify to do business in any jurisdiction where it would not otherwise be required to qualify but for this Section 3(f), (ii) subject itself to general taxation in any
jurisdiction where it would not otherwise be so subject but for this Section 3(f), or (iii) file a general consent to service of process in any such jurisdiction; 

  
 (g) use
commercially reasonable best efforts to cause all Registrable Securities covered by a Registration Statement to be listed on each securities exchange, interdealer quotation system or other market on which similar securities issued by the Company are
then listed; 
 (h) immediately notify the Investors, at any time prior to the end of the Effectiveness Period, upon
discovery that, or upon the happening of any event as a result of which, the Prospectus includes an untrue statement of a material fact or omits to state any material fact required to be stated therein or necessary to make the statements therein not
misleading in light of the circumstances then existing, and promptly prepare, file with the SEC and furnish to such holder a supplement to or an amendment of such Prospectus as may be necessary so that such Prospectus shall not include an untrue
statement of a material fact or omit to state a material fact required to be stated therein or necessary to make the statements therein not misleading in light of the circumstances then existing; and 

(i) otherwise use commercially reasonable best efforts to comply with all applicable rules and regulations of the SEC under the
1933 Act and the 1934 Act, including, without limitation, Rule 172 under the 1933 Act, file any final Prospectus, including any supplement or amendment thereof, with the SEC pursuant to Rule 424 under the 1933 Act, promptly inform the Investors in
writing if, at any time during the Effectiveness Period, the Company does not satisfy the conditions specified in Rule 172 and, as a result thereof, the Investors are required to deliver a Prospectus in connection with any disposition of Registrable
Securities and take such other actions as may be reasonably necessary to facilitate the registration of the Registrable Securities hereunder; and make available to its security holders, as soon as reasonably practicable, but not later than the
Availability Date (as defined below), an earnings statement covering a period of at least twelve (12) months, beginning after the effective date of each Registration Statement, which earnings statement shall satisfy the provisions of
Section 11(a) of the 1933 Act, including Rule 158 promulgated thereunder (for the purpose of this subsection 3(i), “Availability Date” means the 45th day following the end of the fourth fiscal quarter that includes the effective date
of such Registration Statement, except that, if such fourth fiscal quarter is the last quarter of the Company’s fiscal year, “Availability Date” means the 90th day after the end of such fourth fiscal quarter). 

(j) With a view to making available to the Investors the benefits of Rule 144 (or its successor rule) and any other rule or
regulation of the SEC that may at any time permit the Investors to sell shares of Common Stock to the public without registration, the Company covenants and agrees to: (i) make and keep public information available, as those terms are
understood and defined in Rule 144, until the earlier of (A) six months after such date as all of the Registrable Securities may be sold without restriction (including without limitation any restriction relating to the availability of current
public information about the Company) by the holders thereof pursuant to Rule 144 or any other rule of similar effect or (B) such date as all of the Registrable Securities shall have been resold; (ii) file with the SEC in a timely manner
all reports and other documents required of the Company under the 1934 Act; and (iii) furnish to each Investor upon request, as long as such Investor owns any Registrable Securities, (A) a written statement by the Company that it has
complied with the reporting requirements of the 1934 Act, (B) a copy of the Company’s most recent Annual Report on Form 10-K or Quarterly Report on Form 10-Q, and (C) such other information as may be reasonably requested in order to
avail such Investor of any rule or regulation of the SEC that permits the selling of any such Registrable Securities without registration. 

  
 4. [RESERVED]

 5. Obligations of the Investors. 
 (a) Each Investor shall furnish in writing to the Company such information regarding itself, the Registrable Securities held by it and the intended method of disposition of the Registrable Securities
held by it, as shall be reasonably required to effect the registration of such Registrable Securities and shall execute such documents in connection with such registration as the Company may reasonably request, including but not limited to the
Selling Stockholder Notice and Questionnaire attached hereto as Exhibit B (the “Questionnaire”). At least five (5) Business Days prior to the first anticipated filing date of any Registration Statement, the Company
shall notify each Investor of the information the Company requires from such Investor in connection with the filing of the Registration Statement. The Company shall be obligated to include as a selling stockholder in such Registration Statement
each Investor that provides such information (including the Questionnaire) to the Company at least two (2) Business Days prior to the first anticipated filing date of such Registration Statement and the Company shall not be obligated to
register the Registrable Securities of any Investor that does not provide such information (including the Questionnaire) by such date. 
 (b) Each Investor, by its acceptance of the Registrable Securities agrees to cooperate with the Company as reasonably requested by the Company in connection with the preparation and filing of a
Registration Statement hereunder, unless such Investor has notified the Company in writing of its election to exclude all of its Registrable Securities from such Registration Statement. 

(c) Each Investor agrees that, upon receipt of any notice from the Company of either (i) the commencement of an Allowed Delay
pursuant to Section 2(c)(ii) or (ii) the happening of an event pursuant to Section 3(h) hereof, such Investor will immediately discontinue disposition of Registrable Securities pursuant to the Registration Statement covering such
Registrable Securities, until the Investor is advised by the Company that such dispositions may again be made. 

6. Indemnification. 
 (a) Indemnification by the Company. The Company will indemnify and hold harmless each Investor and its officers, directors, members, employees and agents, successors and assigns, and each
other person, if any, who controls such Investor within the meaning of the 1933 Act, against any losses, claims, damages, liabilities or expenses (including reasonable attorney’s fees), joint or several, to which they may become subject under
the 1933 Act or otherwise, insofar as such losses, claims, damages or liabilities or expenses (or actions in respect thereof) arise out of or are based upon: (i) any untrue statement or alleged untrue statement of any material fact contained in
any Registration Statement, any preliminary Prospectus or final Prospectus, or any amendment or supplement thereof, or the omission or alleged omission to state a material fact required to be stated or necessary to make the statements therein
misleading; (ii) any blue sky application or other document executed by the Company specifically for that purpose or based upon written information furnished by the Company filed in any state or other jurisdiction in order to qualify any or all
of the Registrable Securities under the securities laws thereof (any such application, document or information herein called a “Blue Sky Application”); (iii) the omission or alleged omission to state in a Blue Sky Application a
material fact required to be stated therein or necessary to make the statements therein not misleading; (iv) any violation by the Company or its agents of any rule or regulation promulgated under the 1933 Act applicable to the Company or its
agents and relating to action or inaction required of the Company in connection with such registration; or (v) any failure to register or qualify the Registrable Securities included in any such Registration Statement in any state where the
Company or its agents has affirmatively undertaken or agreed in writing that the Company will undertake such registration or qualification on an Investor’s behalf and will reimburse such Investor, and each such officer, director, member,
employee and agent, successors and assigns, and each such controlling person for any legal or other expenses reasonably incurred by them in connection with investigating or defending any such loss, claim, damage, liability or action;
provided, however, that the Company will not be liable in any such case if and to the extent that any such loss, claim, damage, liability or expense arises out of or is based upon an untrue statement or alleged untrue statement or
omission or alleged omission so made in conformity with information furnished by such Investor or any such controlling person in writing specifically for use in such Registration Statement or Prospectus. 

  

(b) Indemnification by the Investors. Each Investor agrees, severally but not jointly, to indemnify and hold harmless,
to the fullest extent permitted by law, the Company, its directors, officers, employees, stockholders and each person who controls the Company (within the meaning of the 1933 Act) against any losses, claims, damages, liabilities and expense
(including reasonable attorneys’ fees) resulting from any untrue statement of a material fact or any omission of a material fact required to be stated in the Registration Statement or Prospectus or preliminary Prospectus or amendment or
supplement thereto or necessary to make the statements therein not misleading, to the extent, but only to the extent that such untrue statement or omission is contained in any information furnished in writing by such Investor to the Company
specifically for inclusion in such Registration Statement or Prospectus or amendment or supplement thereto. In no event shall the liability of an Investor be greater in amount than the dollar amount of the proceeds (net of all expense paid by
such Investor in connection with any claim relating to this Section 6, the amount of any damages such Investor has otherwise been required to pay by reason of such untrue statement or omission and any underwriting discounts and commissions)
received by such Investor upon the sale of the Registrable Securities included in the Registration Statement giving rise to such indemnification obligation. 
 (c) Conduct of Indemnification Proceedings. Any person entitled to indemnification hereunder shall (i) give prompt notice to the indemnifying party of any claim with respect to which
it seeks indemnification and (ii) permit such indemnifying party to assume the defense of such claim with counsel reasonably satisfactory to the indemnified party; provided that any person entitled to indemnification hereunder shall have
the right to employ separate counsel and to participate in the defense of such claim, but the fees and expenses of such counsel shall be at the expense of such person unless (a) the indemnifying party has agreed to pay such fees or expenses, or
(b) the indemnifying party shall have failed to assume the defense of such claim and employ counsel reasonably satisfactory to such person or (c) in the reasonable judgment of any such person, based upon written advice of its counsel, a
conflict of interest exists between such person and the indemnifying party with respect to such claims (in which case, if the person notifies the indemnifying party in writing that such person elects to employ separate counsel at the expense of the
indemnifying party, the indemnifying party shall not have the right to assume the defense of such claim on behalf of such person); and provided, further, that the failure of any indemnified party to give notice as provided herein shall
not relieve the indemnifying party of its obligations hereunder, except to the extent that such failure to give notice shall materially adversely affect the indemnifying party in the defense of any such claim or litigation. It is understood
that the indemnifying party shall not, in connection with any single proceeding in the same jurisdiction, be liable for fees or expenses of more than one separate firm of attorneys at any time for all indemnified parties. No indemnifying party
will, except with the consent of the indemnified party, consent to entry of any judgment or enter into any settlement that does not include as an unconditional term thereof the giving by the claimant or plaintiff to such indemnified party of a
release from all liability in respect of such claim or litigation. 

  

(d) Contribution. If for any reason the indemnification provided for in the preceding paragraphs (a) and
(b) is unavailable to an indemnified party or insufficient to hold it harmless, other than as expressly specified therein, then the indemnifying party shall contribute to the amount paid or payable by the indemnified party as a result of such
loss, claim, damage, liability or expense in such proportion as is appropriate to reflect the relative fault of the indemnified party and the indemnifying party, as well as any other relevant equitable considerations. No person guilty of
fraudulent misrepresentation within the meaning of Section 11(f) of the 1933 Act shall be entitled to contribution from any person not guilty of such fraudulent misrepresentation. In no event shall the contribution obligation of a holder
of Registrable Securities be greater in amount than the dollar amount of the proceeds (net of all expenses paid by such holder in connection with any claim relating to this Section 6, the amount of any damages such holder has otherwise been
required to pay by reason of such untrue or alleged untrue statement or omission or alleged omission and any underwriter discounts and commissions) received by it upon the sale of the Registrable Securities giving rise to such contribution
obligation. 
 7. Miscellaneous. 
 (a) Amendments and Waivers. This Agreement may be amended only by a writing signed by the Company and the Required Investors. The Company may take any action herein prohibited, or
omit to perform any act herein required to be performed by it, only if the Company shall have obtained the written consent to such amendment, action or omission to act, of the Required Investors. 

(b) Notices. All notices and other communications provided for or permitted hereunder shall be made as set forth in the
Purchase Agreement. 
 (c) Assignments and Transfers by Investors. The provisions of this Agreement shall be
binding upon and inure to the benefit of the Investors and their respective successors and assigns. An Investor may transfer or assign, in whole or from time to time in part, to one or more persons its rights hereunder in connection with the
transfer of Registrable Securities by such Investor to such person, provided that such Investor complies with all laws applicable thereto and provides written notice of assignment to the Company promptly after such assignment is effected.

  

(d) Assignments and Transfers by the Company. This Agreement may not be assigned by the Company (whether by operation of
law or otherwise) without the prior written consent of the Required Investors, provided, however, that the Company may assign its rights and delegate its duties hereunder to any surviving or successor corporation in connection with a merger or
consolidation of the Company with another corporation, or a sale, transfer or other disposition of all or substantially all of the Company’s assets to another corporation, without the prior written consent of the Required Investors, after
notice duly given by the Company to each Investor. 
 (e) Benefits of the Agreement. The terms and conditions
of this Agreement shall inure to the benefit of and be binding upon the respective permitted successors and assigns of the parties. Nothing in this Agreement, express or implied, is intended to confer upon any party other than the parties
hereto or their respective successors and assigns any rights, remedies, obligations, or liabilities under or by reason of this Agreement, except as expressly provided in this Agreement. 

(f) Counterparts; Faxes. This Agreement may be executed in two or more counterparts, each of which shall be deemed an
original, but all of which together shall constitute one and the same instrument. This Agreement may also be executed via facsimile, which shall be deemed an original. 
 (g) Titles and Subtitles. The titles and subtitles used in this Agreement are used for convenience only and are not to be considered in construing or interpreting this Agreement.

 (h) Severability. Any provision of this Agreement that is prohibited or unenforceable in any jurisdiction
shall, as to such jurisdiction, be ineffective to the extent of such prohibition or unenforceability without invalidating the remaining provisions hereof but shall be interpreted as if it were written so as to be enforceable to the maximum extent
permitted by applicable law, and any such prohibition or unenforceability in any jurisdiction shall not invalidate or render unenforceable such provision in any other jurisdiction. To the extent permitted by applicable law, the parties hereby
waive any provision of law which renders any provisions hereof prohibited or unenforceable in any respect. 

(i) Further Assurances. The parties shall execute and deliver all such further instruments and documents and take all
such other actions as may reasonably be required to carry out the transactions contemplated hereby and to evidence the fulfillment of the agreements herein contained. 
 (j) Entire Agreement. This Agreement is intended by the parties as a final expression of their agreement and intended to be a complete and exclusive statement of the agreement and
understanding of the parties hereto in respect of the subject matter contained herein. This Agreement supersedes all prior agreements and understandings between the parties with respect to such subject matter. 

  
 (k) Governing
Law; Consent to Jurisdiction; Waiver of Jury Trial. This Agreement shall be governed by, and construed in accordance with, the internal laws of the State of New York without regard to the choice of law principles thereof. Each of the
parties hereto irrevocably submits to the exclusive jurisdiction of the courts of the State of New York located in New York County and the United States District Court for the Southern District of New York for the purpose of any suit, action,
proceeding or judgment relating to or arising out of this Agreement and the transactions contemplated hereby. Service of process in connection with any such suit, action or proceeding may be served on each party hereto anywhere in the world by
the same methods as are specified for the giving of notices under this Agreement. Each of the parties hereto irrevocably consents to the jurisdiction of any such court in any such suit, action or proceeding and to the laying of venue in such
court. Each party hereto irrevocably waives any objection to the laying of venue of any such suit, action or proceeding brought in such courts and irrevocably waives any claim that any such suit, action or proceeding brought in any such court
has been brought in an inconvenient forum. EACH OF THE PARTIES HERETO WAIVES ANY RIGHT TO REQUEST A TRIAL BY JURY IN ANY LITIGATION WITH RESPECT TO THIS AGREEMENT AND REPRESENTS THAT COUNSEL HAS BEEN CONSULTED SPECIFICALLY AS TO THIS WAIVER.

  
 IN WITNESS WHEREOF,
the parties have executed this Agreement or caused their duly authorized officers to execute this Agreement as of the date first above written. 
  

					
	The Company:	  	 WORLD HEART CORPORATION

			
		  	By:	  	 /s/ Morgan R. Brown

		  	Name:	  	Morgan R. Brown
		  	Title:	  	Executive Vice-President and Chief Financial Officer

  
 IN WITNESS WHEREOF, the parties have
executed this Registration Rights as of the date first written above. 
  

			
	NAME OF INVESTING ENTITY/INDIVIDUAL
	Austin Marxe
	
	AUTHORIZED SIGNATORY
		
	By:	 	/s/ Austin Marxe
		 	By: Austin Marxe
	
	Address for Notice:
	
	Special Situations Fund III QP, L.P.
	 527 Madison Avenue, Suite 2600

	 New York, New York 10022

	
	Telephone No.: 212-319-6670
	
	Email: Austin@ssf.com
	
	NAME OF INVESTING ENTITY/INDIVIDUAL
	David Greenhouse
	
	AUTHORIZED SIGNATORY
	By:	 	/s/ David Greenhouse
		 	By: David Greenhouse
	
	Address for Notice:
	
	c/o Special Situations Funds
	 527 Madison Avenue, Suite 2600

	 New York, New York 10022

	
	Telephone No.: 212-319-6625
	
	Email: david@ssffund.com
	
	NAME OF INVESTING ENTITY/INDIVIDUAL
	Special Situations Fund III QP, L.P.
	Special Situations Cayman Fund, L.P.
	Special Situations Private Equity Fund, L.P.
	Special Situations Life Sciences Fund, L.P.
		
	By:	 	/s/ David Greenhouse
		 	Name: David Greenhouse
		 	Title: General Partner
	
	Address for Notice:
	
	c/o Special Situations Funds
	 527 Madison Avenue, Suite 2600

	 New York, New York 10022

	
	Telephone No.: 212-319-6625
	
	Email: david@ssffund.com
	
	Attention: David Greenhouse

  
 IN WITNESS WHEREOF, the parties have
executed this Registration Rights as of the date first written above. 
  

			
	NAME OF INVESTING ENTITY/INDIVIDUAL
	Venrock Associates V, L.P.
	Venrock Partners V, L.P.
	Venrock Entrepreneurs Fund V, L.P.
		
	By:	 	/s/ David L. Stepp
	Name:	 	David L. Stepp
	Title:	 	Authorized Signatory
	
	Address for Notice:
	
	 c/o David L. Stepp

	 3340 HIllview Avenue

	 Palo Alto, CA 94304

	
	Telephone No.: 650-561-9580
	
	Fax: 650-561-9180
	
	Email: dstepp@venrock.com
	
	Attention: David L. Stepp

  
 IN WITNESS WHEREOF,
the parties have executed this Registration Rights as of the date first written above. 
  

	
	 NAME OF INVESTING ENTITY/INDIVIDUAL
             NEW LEAF VENTURES II, L.P.

	
	Authorized Signatory:
	By: New Leaf Venture Associates II, L.P.
	Its: General Partner
	
	By: New Leaf Venture Management II, L.L.C.
	Its: General Partner
	
	By:  /s/ Craig L. Slutzkin
	Name:  Craig L. Slutzkin
	Title:  Chief Financial Officer
	
	Address for Notice:
	
	7 Times Square, Suite 3502
	New York, NY 10036
	Attention: Craig L. Slutzkin
	Telephone No.: 646-871-6400
	Fax 646-871-6450
	Email:  craig@nlvpartners.com

  
 IN WITNESS WHEREOF, the parties have
executed this Registration Rights as of the date first written above. 
  

			
	NAME OF INVESTING ENTITY/INDIVIDUAL
	Oppenheim Asset Management Services S.ar.l. on behalf of FCPOP Medical BioHe@lth-Trends
	
	Authorized Signatory
		
	By:	 	/s/ Julia Brauckmann
		 	Julia Brauckmann
		 	Title: Vice President
		
	By:	 	/s/ Helene Braun
		 	Helene Braun
		 	Title: Senior Associate
	
	Address for Notice:
	
	 Oppenheim Asset Management Services S.ar.l.
 4 rue Jean Monnet

	L-2180 Luxembourg
	
	Telephone No.: 00352 22 15 22 1
	
	Fax 00352 22 15 22 500
	
	Email: OPAMPre-Trade-KontrolleIM@oppenheim.lu

  
 IN WITNESS WHEREOF, the parties have
executed this Registration Rights as of the date first written above. 
  

	
	NAME OF INVESTING ENTITY/INDIVIDUAL
	THE OSGOOD FAMILY TRUST UAD 4/14/2000
	
	Authorized Signatory
	
	By:  /s/ Richard H. Osgood
	Name:  Richard H. Osgood
	Title:  Richard H. Osgood, Trustee
	
	Address for Notice:
	
	One Bush Street #1700
	San Francisco, CA
94104                                        

	
	Telephone No.: 415-274-6833
	
	Fax 415-274-6887
	
	Email:  rick.osgood@wedbush.com
	
	Attention:  Vinnie Devone

  
 IN WITNESS WHEREOF, the parties have
executed this Registration Rights as of the date first written above. 
  

			
	 NAME OF INVESTING ENTITY/INDIVIDUAL Zeke, LP

	
	Authorized Signatory
		
	By:	 	/s/ Edward N. Antoian
		 	By: Edward N. Antoian
		 	Name: Zeke, LP-6P
	
	Address for Notice:
	
	c/o Chartwell Inv. Partners
	1235 Westlakes Drive, Ste 400
	Berwyn, PA 19312
	
	Telephone No.: 610-407-4829
	
	Fax 610-296-1430
	
	Email: antoian@chartwellip.com
	
	Attention: Ed Antoian

  
 IN WITNESS WHEREOF, the parties have
executed this Registration Rights as of the date first written above. 
  

			
	NAME OF INVESTING ENTITY/INDIVIDUAL
	Pharma/Whealth Management Company S.A. on behalf of Pharma/wHealth
	
	Authorized Signatory
		
	By:	 	/s/ Harold Schwartz
	Name: Harold Schwartz
	Title: General Manager
		
	By:	 	/s/ Stefan Kraft
	Name: Stefan Kraft
	Title: Analyst
	
	Address for Notice:
	
	c/o Pharma/Whealth Management Company S.A.
	4 rue Jean Monnet
	L-2180 Luxembourg
	
	Telephone No.: 00352 22 15 22 1
	
	Fax 00352 22 15 22 500
	
	Email: OPAMPre-Trade-KontrolleIM@oppenheim.lu

  
 IN WITNESS WHEREOF, the parties have
executed this Registration Rights as of the date first written above. 
  

			
	NAME OF INVESTING ENTITY/INDIVIDUAL
	Arthur J. Remillard Jr. Trust
	
	Authorized Signatory
		
	By:	 	Managing Member of Investment Manager
	Name:	 	Stephen Du Bois
	
	Address for Notice:
	101 Huntington Avenue
	Suite 2550
	Boston, MA 02199
	
	Telephone No.: 617-717-6605
	
	Fax 617-717-6688
	
	Email: sgeorge@cambercapital.com

  
 IN WITNESS WHEREOF, the parties have
executed this Registration Rights as of the date first written above. 
  

			
	NAME OF INVESTING ENTITY/INDIVIDUAL
	Ayer Capital Partners Master Fund, L.P.
	
	Authorized Signatory
		
	By:	 	/s/ Jay Venkatesan
	By:	 	Managing Member
	Name:	 	Jay Venkatesan
	
	 Address for Notice:

230 California Street

	Suite 600
	San Francisco, CA 94111
	
	Telephone No.: 415-874-4800
	
	Facsimile No.: 415-520-6826
	
	Email: tmg@ayercapital.com

  
 IN WITNESS WHEREOF, the parties have
executed this Registration Rights as of the date first written above. 
  

			
	NAME OF INVESTING ENTITY/INDIVIDUAL
	Ayer Capital Partners Kestrel Fund, LP
	
	Authorized Signatory
		
	By:	 	/s/ Jay Venkatesan
	By:	 	Managing Member
	Name:	 	Jay Venkatesan

  

	
	Address for Notice:
	c/o Ayer Capital Management
	230 California Street
	Suite 600
	San Francisco, CA 94111
	
	Telephone No.: 415-874-4800
	
	Facsimile No.: 415-520-6826
	
	Email: tmg@ayercapital.com

  
 IN WITNESS WHEREOF, the parties have
executed this Registration Rights as of the date first written above. 
  

			
	NAME OF INVESTING ENTITY/INDIVIDUAL
	Camber Capital Fund II, LP
	
	Authorized Signatory
		
	By:	 	/s/ Stephen Du Bois
	By:	 	Managing Member of Investment Manager
	Name:	 	Stephen Du Bois

  

	
	Address for Notice:
	
	c/o Camber Capital Management, LLC
	101 Huntington Avenue
	Suite 2550
	Boston, MA 02199
	
	Telephone No.: 617-717-6605
	
	Fax: 617-717-6688
	
	Email: sgeorge@cambercapital.com

  
 IN WITNESS WHEREOF, the parties have
executed this Registration Rights as of the date first written above. 
  

			
	NAME OF INVESTING ENTITY/INDIVIDUAL
	Camber Capital Master Fund, LP
	
	Authorized Signatory
	
	By:  /s/ Stephen Du Bois
	Name:  Stephen Du Bois
	Title:    Managing Member of Investment Manager

 

	
	Address for Notice:
	
	c/o Camber Capital Management, LLC
	101 Huntington Avenue
	Suite 2550
	Boston, MA 02199
	
	Telephone No.: 617-717-6605
	
	Email: sgeorge@cambercapital.com

  
 IN WITNESS WHEREOF, the parties have
executed this Registration Rights as of the date first written above. 
  

			
	NAME OF INVESTING ENTITY/INDIVIDUAL
	Cougar Trading, LLC
	
	Authorized Signatory
	
	By:  /s/ Carl J. Bennett
	By:    Chief Financial Officer
	Name:  Carl J. Bennett

  

	
	Address for Notice:
	
	1370 Avenue of the Americas
	30th Floor
	New York, NY 10019
	
	Telephone No.: 212-702-0693
	
	Email: cbennett@cougartrading.com

  
 IN WITNESS WHEREOF, the parties have
executed this Registration Rights as of the date first written above. 
  

			
	NAME OF INVESTING ENTITY/INDIVIDUAL
	Cranshire Capital LP
	
	Authorized Signatory
	
	By:  /s/ Keith A. Goodman
	By:    COO, Downsview Capital Inc., The General Partner
	Name:  Keith A. Goodman
	
	Address for Notice:
	
	Cranshire Capital LP
	3100 Dundee Road, Ste 703
	Northbrook, IL 60062
	
	Telephone No.: 847-562-9030
	
	 Email:mkopin@cranshirecapital.com /
 kgoodman@cranshirecapital.com

  
 IN WITNESS WHEREOF, the parties have
executed this Registration Rights as of the date first written above. 
  

			
	NAME OF INVESTING ENTITY/INDIVIDUAL
	DAFNA LifeScience Ltd
	
	Authorized Signatory
		
	By:	 	/s/ Nathan Fischel
	By:	 	Managing Member
	Name:	 	Nathan Fischel

  

	
	Address for Notice:
	
	10990 Wilshire Blvd., #1400
	Los Angeles, CA 90024
	
	Telephone No.: 310-954-3200
	
	Fax: 310-445-6594
	
	Email: dfische@dafnacapital.com

  
 IN WITNESS WHEREOF, the parties have
executed this Registration Rights as of the date first written above. 
  

			
	NAME OF INVESTING ENTITY/INDIVIDUAL
	DAFNA LifeScience Select Ltd
	
	Authorized Signatory
		
	By:	 	/s/ Nathan Fischel
	By:	 	Managing Member
	Name:	 	Nathan Fischel

  

	
	Address for Notice:
	
	10990 Wilshire Blvd., #1400
	Los Angeles, CA 90024
	
	Telephone No.: 310-954-3200
	
	Fax: 310-445-6594
	
	Email: dfische@dafnacapital.com

  
 IN WITNESS WHEREOF, the parties have
executed this Registration Rights as of the date first written above. 
  

			
	NAME OF INVESTING ENTITY/INDIVIDUAL
	DAFNA LifeScience Market Neutral Ltd
	
	Authorized Signatory
		
	By:	 	/s/ Nathan Fischel
	By:	 	Managing Member
	Name:	 	Nathan Fischel

  

	
	Address for Notice:
	
	10990 Wilshire Blvd., #1400
	Los Angeles, CA 90024
	
	Telephone No.: 310-954-3200
	
	Fax: 310-445-6594
	
	Email: dfische@dafnacapital.com

  
 IN WITNESS WHEREOF, the parties have
executed this Registration Rights as of the date first written above. 
  

			
	NAME OF INVESTING ENTITY/INDIVIDUAL
	Deerfield Special Situations Fund LP
	
	Authorized Signatory
		
	By:	 	/s/ James Flynn

			
	By:	 	General Partner

			
	Name:	 	James Flynn
	
	Address for Notice:
	
	780 3rd Avenue, 37th
Floor
	New York NY 10017
	
	Telephone No.: 212-551-1600
	
	Fax: 212-551-1612
	
	Email: dlevine@deerfieldpartners.com

  
 IN WITNESS WHEREOF, the parties have
executed this Registration Rights as of the date first written above. 
  

			
	NAME OF INVESTING ENTITY/INDIVIDUAL
	Deerfield Special Situations Fund International, LTD
	
	Authorized Signatory
		
	By:	 	/s/ James Flynn

			
	By:	 	General Partner

			
	Name:	 	James Flynn
	
	Address for Notice:
	
	780 3rd Avenue, 37th
Floor
	New York NY 10017
	
	Telephone No.: 212-551-1600
	
	Fax: 212-551-1612
	
	Email: dlevine@deerfieldpartners.com

  
 IN WITNESS WHEREOF, the parties have
executed this Registration Rights as of the date first written above. 
  

			
	NAME OF INVESTING ENTITY/INDIVIDUAL
	Hartz Capital Investments, LLC
	
	Authorized Signatory
	
	By: Empery Asset Management, LP, it’s authorized agent
		
	By:	 	/s/ Ryan Lane

			
	By:	 	Managing Partner of the GP

			
	Name:	 	Ryan Lane
	
	Address for Notice:
	
	120 Broadway, Suite 1019
	New York NY 10271
	
	Telephone No.: 212-608-3300
	
	Email: notices@emperyam.com

  
 IN WITNESS WHEREOF, the parties have
executed this Registration Rights as of the date first written above. 
  

			
	NAME OF INVESTING ENTITY/INDIVIDUAL
	Empery Asset Master, LTD
	
	Authorized Signatory
		
	By:	 	Empery Asset Management, LP, it’s authorized agent
		
	By:	 	/s/ Ryan Lane
	By:	 	Managing Partner of the GP
	Name:	 	Ryan Lane
	
	Address for Notice:
	
	120 Broadway, Suite 1019
	New York NY 10271
	
	Telephone No.: 212-608-3300
	
	Fax 212-608-3307
	
	Email: notices@emperyam.com

  
 IN WITNESS WHEREOF, the parties have
executed this Registration Rights as of the date first written above. 
  

			
	NAME OF INVESTING ENTITY/INDIVIDUAL
	Epworth-Ayer Capital
	
	Authorized Signatory
		
	By:	 	/s/ Jay Venkatesan
	By:	 	Managing Member of Investment Advisor
	Name:	 	Jay Venkatesan
	
	Address for Notice:
	
	c/o Ayer Capital Management
	230 California Street
	Suite 600
	San Francisco, CA 94111
	
	Telephone No.: 415-874-4800
	
	Facsimile No.: 415-520-6826
	
	Email: tmg@ayercapital.com

  
 IN WITNESS WHEREOF, the parties have
executed this Registration Rights as of the date first written above. 
  

			
	NAME OF INVESTING ENTITY/INDIVIDUAL
	Freestone Advantage Partners, LP
	
	Authorized Signatory
		
	By:	 	/s/ Keith A. Goodman
	By:	 	Manager
	Name:	 	Keith A. Goodman
	
	Address for Notice:
	
	c/o Downsview Capital, Inc.
	3100 Dundee Road, Ste 703
	Northbrook, IL 60062
	
	Telephone No.: 847-562-9030
	
	Fax: 847-562-9031
	
	Email:mkopin@cranshirecapital.com kgoodman@cranshirecapital.com

  
 IN WITNESS WHEREOF, the parties have
executed this Registration Rights as of the date first written above. 
  

			
	NAME OF INVESTING ENTITY/INDIVIDUAL
	IPConcept Fund Management S.A., an administration company according to Luxembourg Law, acting in its own name but on behalf of Apo Medical Opportunities – Medical
Strategy (“ICP”)
	
	Authorized Signatory
		
	By:	 	/s/ Matthias Schirpke
	By:	 	CEO
	Name:	 	Matthias Schirpke
		
	By:	 	/s/ Marco Onischschenko
	By:	 	Proxy
	Name:	 	Marco Onischschenko
	
	Address for Notice:
	
	IPConcept Fund Management S.A.
	4, rue Thomas-Edison
	L-1445 Luxembourg
	Attention: Mr. Matthias Schirpke
	
	Telephone No.: 352-2602-484950
	
	Fax 352-2602-484955
	
	Email: amc@ipconcept.lu

  
 IN WITNESS WHEREOF, the parties have
executed this Registration Rights as of the date first written above. 
  

	
	NAME OF INVESTING ENTITY/INDIVIDUAL
	Iroquois Master Fund Ltd.
	
	Authorized Signatory
	By:        /s/ Joshua Silverman
	By:  Authorized Signer
	Name:  Joshua Silverman
	
	Address for Notice:
	
	641 Lexington Avenue, 26th Floor
	
	New York, NY 10022
	
	Telephone No.: 212-924-3070
	
	Email: jsilvermant@icfund.com

  
 IN WITNESS WHEREOF, the parties have
executed this Registration Rights as of the date first written above. 
  

					
	NAME OF INVESTING ENTITY/INDIVIDUAL
	Jalu Capital Partners LP
	
	Authorized Signatory
	By:	 	/s Mark Fain
		 	Name:	 	Mark Fain
		 	By:	 	Managing Partner
	
	Address for Notice:
	
	c/o Mark Fain
	39 Hewlett Lane
	Fort Washington, NY 10050
	
	Telephone No.: 516-439-5392
	
	Fax 516-439-5391
	
	Email: mark@jalucapital.com

  
 IN WITNESS WHEREOF, the parties have
executed this Registration Rights as of the date first written above. 
  

			
	NAME OF INVESTING ENTITY/INDIVIDUAL
	J. Goldman Master Fund L.P.
	
	By: /s/
                                
	Name:
                                
	Title:
                                  
	
	Address for Notice:
	
	152 West 57th Street, 48th
Floor
	New York, NY 10019
	
	Telephone No.: 212-262-4268
	
	Fax 212-262-4349
	
	Email: areback@jgoldman.net

  
 Exhibit A

 Plan of Distribution 
 The selling stockholders, which as used herein includes donees, pledgees, transferees or other successors-in-interest selling shares of common stock or interests in shares of common stock received after
the date of this prospectus from a selling stockholder as a gift, pledge, partnership distribution or other transfer, may, from time to time, sell, transfer or otherwise dispose of any or all of their shares of common stock or interests in shares of
common stock on any stock exchange, market or trading facility on which the shares are traded or in private transactions. These dispositions may be at fixed prices, at prevailing market prices at the time of sale, at prices related to the
prevailing market price, at varying prices determined at the time of sale, or at negotiated prices. 
 The selling stockholders
may use any one or more of the following methods when disposing of shares or interests therein: 
  

	 	•	 	 ordinary brokerage transactions and transactions in which the broker-dealer solicits purchasers; 

 

	 	•	 	 block trades in which the broker-dealer will attempt to sell the shares as agent, but may position and resell a portion of the block as principal to
facilitate the transaction; 

  

	 	•	 	 purchases by a broker-dealer as principal and resale by the broker-dealer for its account; 

 

	 	•	 	 an exchange or over-the-counter distribution in accordance with the rules of the applicable exchange or other market;

  

	 	•	 	 privately negotiated transactions; 

  

	 	•	 	 short sales effected after the date the registration statement of which this Prospectus is a part is declared effective by the SEC;

  

	 	•	 	 through the writing or settlement of options or other hedging transactions, whether through an options exchange or otherwise;

  

	 	•	 	 broker-dealers may agree with the selling stockholders to sell a specified number of such shares at a stipulated price per share;

  

	 	•	 	 a combination of any such methods of sale; and 

  

	 	•	 	 any other method permitted by applicable law. 

  
 1 

  
 The selling
stockholders may, from time to time, pledge or grant a security interest in some or all of the shares of common stock owned by them and, if they default in the performance of their secured obligations, the pledgees or secured parties may offer and
sell the shares of common stock, from time to time, under this prospectus, or under an amendment to this prospectus under Rule 424(b)(3) or other applicable provision of the Securities Act amending the list of selling stockholders to
include the pledgee, transferee or other successors in interest as selling stockholders under this prospectus. The selling stockholders also may transfer the shares of common stock in other circumstances, in which case the transferees, pledgees
or other successors in interest will be the selling beneficial owners for purposes of this prospectus. 
 In connection with the
sale of our common stock or interests therein, the selling stockholders may enter into hedging transactions with broker-dealers or other financial institutions, which may in turn engage in short sales of the common stock in the course of hedging the
positions they assume. The selling stockholders may also sell shares of our common stock short and deliver these securities to close out their short positions, or loan or pledge the common stock to broker-dealers that in turn may sell these
securities. The selling stockholders may also enter into option or other transactions with broker-dealers or other financial institutions or the creation of one or more derivative securities which require the delivery to such broker-dealer or
other financial institution of shares offered by this prospectus, which shares such broker-dealer or other financial institution may resell pursuant to this prospectus (as supplemented or amended to reflect such transaction). 

The aggregate proceeds to the selling stockholders from the sale of the common stock offered by them will be the purchase price of the
common stock less discounts or commissions, if any. Each of the selling stockholders reserves the right to accept and, together with their agents from time to time, to reject, in whole or in part, any proposed purchase of common stock to be
made directly or through agents. We will not receive any of the proceeds from this offering. Upon any exercise of the warrants by payment of cash, however, we will receive the exercise price of the warrants. 

The selling stockholders also may resell all or a portion of the shares in open market transactions in reliance upon Rule 144 under
the Securities Act of 1933, provided that they meet the criteria and conform to the requirements of that rule. 
 The selling
stockholders and any underwriters, broker-dealers or agents that participate in the sale of the common stock or interests therein may be “underwriters” within the meaning of Section 2(11) of the Securities Act. Any discounts,
commissions, concessions or profit they earn on any resale of the shares may be underwriting discounts and commissions under the Securities Act. Selling stockholders who are “underwriters” within the meaning of Section 2(11) of
the Securities Act will be subject to the prospectus delivery requirements of the Securities Act. 
 To the extent required, the
shares of our common stock to be sold, the names of the selling stockholders, the respective purchase prices and public offering prices, the names of any agents, dealer or underwriter, any applicable commissions or discounts with respect to a
particular offer will be set forth in an accompanying prospectus supplement or, if appropriate, a post-effective amendment to the registration statement that includes this prospectus. 

In order to comply with the securities laws of some states, if applicable, the common stock may be sold in these jurisdictions only
through registered or licensed brokers or dealers. In addition, in some states the common stock may not be sold unless it has been registered or qualified for sale or an exemption from registration or qualification requirements is available and
is complied with. 

  
 2 

  
 We have advised the
selling stockholders that the anti-manipulation rules of Regulation M under the Exchange Act may apply to sales of shares in the market and to the activities of the selling stockholders and their affiliates. In addition, to the extent
applicable we will make copies of this prospectus (as it may be supplemented or amended from time to time) available to the selling stockholders for the purpose of satisfying the prospectus delivery requirements of the Securities Act. The
selling stockholders may indemnify any broker-dealer that participates in transactions involving the sale of the shares against certain liabilities, including liabilities arising under the Securities Act. 

We have agreed to indemnify the selling stockholders against liabilities, including liabilities under the Securities Act and state
securities laws, relating to the registration of the shares offered by this prospectus. 
 We have agreed with the selling
stockholders to keep the registration statement of which this prospectus constitutes a part effective until the earlier of (1) such time as all of the shares covered by this prospectus have been disposed of pursuant to and in accordance with
the registration statement or (2) the date on which the shares may be sold without restriction pursuant to Rule 144 of the Securities Act. 

  
 3 

  
 Exhibit B

 WORLD HEART CORPORATION 
 SELLING STOCKHOLDER NOTICE AND QUESTIONNAIRE 
 The undersigned holder of
shares of the common stock of World Heart Corporation, a Delaware corporation (the “Company”), issued pursuant to a certain Securities Purchase Agreement by and among the Company and the Purchasers named therein, dated as of
            , 2010 (the “Agreement”), understands that the Company intends to file with the Securities and Exchange Commission a registration statement on
Form S-3 (the “Resale Registration Statement”) for the registration and the resale under Rule 415 of the Securities Act of 1933, as amended (the “Securities Act”), of the Registrable
Securities in accordance with the terms of the Registration Rights Agreement, dated             , 2010, (the “Registration Rights Agreement”), between the Company
and the purchasers signatory thereto. All capitalized terms not otherwise defined herein shall have the meanings ascribed thereto in the Registration Rights Agreement. 
 In order to sell or otherwise dispose of any Registrable Securities pursuant to the Resale Registration Statement, a holder of Registrable Securities generally will be required to be named as a selling
stockholder in the related prospectus or a supplement thereto (as so supplemented, the “Prospectus”), deliver the Prospectus to purchasers of Registrable Securities (including pursuant to Rule 172 under the Securities
Act) and be bound by the provisions of the Agreement (including certain indemnification provisions, as described below). Holders must complete and deliver this Notice and Questionnaire in order to be named as selling stockholders in the
Prospectus. Holders of Registrable Securities who do not complete, execute and return this Notice and Questionnaire will not be named as selling stockholders in the Resale Registration Statement or the Prospectus and may not use the
Prospectus for resales of Registrable Securities. 
 Certain legal consequences arise from being named as a selling
stockholder in the Resale Registration Statement and the Prospectus. Holders of Registrable Securities are advised to consult their own securities law counsel regarding the consequences of being named or not named as a selling stockholder in the
Resale Registration Statement and the Prospectus. 
 NOTICE 

The undersigned holder (the “Selling Stockholder”) of Registrable Securities hereby gives notice to the Company
of its intention to sell or otherwise dispose of Registrable Securities owned by it and listed below in Item (3), unless otherwise specified in Item (3), pursuant to the Resale Registration Statement. The undersigned, by signing and returning this
Notice and Questionnaire, understands and agrees that it will be bound by the terms and conditions of this Notice and Questionnaire and the Agreement. 
 The undersigned hereby provides the following information to the Company and represents and warrants that such information is accurate and complete: 

  
 1 

  
 QUESTIONNAIRE

  

					
	1.	  	Name.	 	
			
		  	(a)	 	Full Legal Name of Selling Stockholder:
			
		  	(b)	 	Full Legal Name of Registered Holder (if not the same as (a) above) through which Registrable Securities Listed in Item 3 below are held:
			
		  	(c)	 	Full Legal Name of each natural person who directly or indirectly, alone or with others, has power to vote or dispose of the securities covered by the
questionnaire:
		
	2.	  	Address for Notices to Selling Stockholder:
		
		  	Telephone:
		
		  	Fax:
		
		  	Contact Person:
		
		  	E-mail address of Contact Person:

  
 2 

  

							
	3.	  	Beneficial Ownership of Registrable Securities:	  	
				
		  	(a)	  	Type and Number of Registrable Securities beneficially owned (including shares of common stock issuable upon the exercise of warrants):	  	
				
		  	(b)	  	Number of shares of common stock to be registered pursuant to this Notice for resale:	  	
			
	4.	  	Broker-Dealer Status:	  	
				
		  	(a)	  	Are you a broker-dealer?	  	
			
		  		  	Yes  ̈
                    No  ̈
			
		  	(b)	  	If “yes” to Section 4(a), did you receive your Registrable Securities as compensation for investment banking services to the Company?
			
		  		  	Yes  ̈
                    No  ̈
			
		  	Note:	  	If no, the Commission’s staff has indicated that you should be identified as an underwriter in the Registration Statement.
			
		  	(c)	  	Are you an affiliate of a broker-dealer?
			
		  		  	Yes  ̈
                    No  ̈
			
		  	Note:	  	If yes, provide a narrative explanation below:

  
 3 

  

							
			
	 	  	(c)	  	If you are an affiliate of a broker-dealer, do you certify that you bought the Registrable Securities in the ordinary
course of business, and at the time of the
purchase of the Registrable Securities to be resold, you had no agreements or
understandings, directly or indirectly, with any person to distribute the Registrable Securities?
			
		  		  	Yes  ̈
                    No  ̈
			
		  	Note:	  	If no, the Commission’s staff has indicated that you should be identified as an underwriter in the Registration Statement.
		
	5.	  	Beneficial Ownership of Other Securities of the Company Owned by the Selling Stockholder.
		
		  	Except as set forth below in this Item 5, the undersigned is not the beneficial or registered owner of any securities of the Company other than the Registrable
Securities listed above in Item 3.
			
		  	(a)	  	Type and amount of other securities beneficially owned:
		
	6.	  	Relationships with the Company:
		
		  	Except as set forth below, neither the undersigned nor any of its affiliates, officers, directors or principal equity holders (owners of 5% of more of the equity
securities of the undersigned) has held any position or office or has had any other material relationship with the Company (or its predecessors or affiliates) during the past three years.
		
		  	State any exceptions here:
		
	7.	  	Plan of Distribution:

 The undersigned has reviewed the form of Plan of Distribution attached as Exhibit A to the Registration Rights Agreement, and hereby confirms that, except as set forth below, the information
contained therein regarding the undersigned and its plan of distribution is correct and complete. 

  
 4 

  
 State any exceptions here: 

*********** 

The undersigned agrees to promptly notify the Company of any inaccuracies or changes in the information provided herein that may occur
subsequent to the date hereof and prior to the effective date of any applicable Resale Registration Statement. All notices hereunder and pursuant to the Agreement shall be made in writing, by hand delivery, confirmed or facsimile transmission,
first-class mail or air courier guaranteeing overnight delivery at the address set forth below. In the absence of any such notification, the Company shall be entitled to continue to rely on the accuracy of the information in this Notice and
Questionnaire. 
 By signing below, the undersigned consents to the disclosure of the information contained herein in its
answers to Items (1) through (7) above and the inclusion of such information in the Resale Registration Statement and the Prospectus. The undersigned understands that such information will be relied upon by the Company in connection with
the preparation or amendment of any such Registration Statement and the Prospectus. 
 By signing below, the undersigned
acknowledges that it understands its obligation to comply, and agrees that it will comply, with the provisions of the Exchange Act and the rules and regulations thereunder, particularly Regulation M in connection with any offering of
Registrable Securities pursuant to the Resale Registration Statement. The undersigned also acknowledges that it understands that the answers to this Questionnaire are furnished for use in connection with Registration Statements filed pursuant to the
Registration Rights Agreement and any amendments or supplements thereto filed with the Commission pursuant to the Securities Act. 
 The undersigned hereby acknowledges and is advised of the following Interpretation A.65 of the July 1997 SEC Manual of Publicly Available Telephone Interpretations regarding short selling:

 “An Issuer filed a Form S-3 registration statement for a secondary offering of common stock which is not yet
effective. One of the selling stockholders wanted to do a short sale of common stock “against the box” and cover the short sale with registered shares after the effective date. The issuer was advised that the short sale could not be made
before the registration statement become effective, because the shares underlying the short sale are deemed to be sold at the time such sale is made. There would, therefore, be a violation of Section 5 if the shares were effectively sold prior
to the effective date.” 
 By returning this Questionnaire, the undersigned will be deemed to be aware of the foregoing
interpretation. 

  
 5 

  
 I confirm that, to the
best of my knowledge and belief, the foregoing statements (including without limitation the answers to this Questionnaire) are correct. 
 IN WITNESS WHEREOF the undersigned, by authority duly given, has caused this Questionnaire to be executed and delivered either in person or by its duly authorized agent. 

 

					
	Dated:                    	 	Beneficial Owner:
			
		 	By:	 	  

		 		 	Name:
		 		 	Title:

 PLEASE FAX A COPY OF THE COMPLETED AND EXECUTED
NOTICE AND QUESTIONNAIRE, AND RETURN THE ORIGINAL BY OVERNIGHT MAIL, TO: 
 Hans Riegels 

Cooley LLP 

Five Palo Alto Square 
 3000 El Camino Real 
 Palo Alto, CA 94306-2155 

Tel: (650) 843-5153 
 Fax: (650) 644-3269 
 Email: hriegels@cooley.com 

  
 65th Amended and Restated Stock Restriction and Co-Sale Agreement

  
 Exhibit 4.2

 EXECUTION VERSION 
 FIFTH AMENDED AND RESTATED 
 STOCK RESTRICTION AND CO-SALE
AGREEMENT 
 FIFTH AMENDED AND RESTATED STOCK RESTRICTION AND CO-SALE AGREEMENT made this 20th day of
December, 2007 by and among (i) Kayak Software Corporation, a Delaware corporation (the “Company”), (ii) holders of Common Stock, or options or warrants to acquire Common Stock whose names are set forth under the
heading “Holders” on Schedule I hereto and each person who shall, after the date hereof, acquire shares of Common Stock (or options or warrants to acquire Common Stock) and join in and become a party to this Agreement by executing
and delivering to the Company an Instrument of Accession in the form of Schedule II hereto (the persons described in this clause (ii) being referred to collectively as the “Holders” and singularly as a
“Holder”) and (iii) those persons whose names are set forth under the heading “Investors” on Schedule I hereto (the persons described in this clause (iii) being referred to collectively as the
“Investors”). The Holders and Investors are collectively referred to herein as the “Stockholders”. 
 WITNESSETH: 
 WHEREAS, the Holders currently own shares of
the Company’s Common Stock, par value $.00l per share (the “Common Stock”) and the Purchaser Warrants (as defined below); and 
 WHEREAS, certain of the Investors have heretofore purchased from the Company an aggregate of (i) six million six hundred thousand (6,600,000) shares of the Company’s Series A
Convertible Preferred Stock, par value $.001 per share (the “Series A Stock”), (ii) one million one hundred seventy six thousand fifty one (1,176,051) shares of the Company’s Series A-1 Convertible Preferred
Stock, par value $.001 per share (the “Series A-1 Stock”, and collectively with the Series A Stock, the “Series A Preferred Stock”), (iii) four million nine hundred eighty nine thousand three
hundred eight (4,989,308) shares of the Company’s Series B Convertible Preferred Stock, par value $.00l per share (the “Series B Stock”), (iv) two million one hundred thirty eight thousand two hundred seventy
five (2,138,275) shares of the Company’s Series B-1 Convertible Preferred Stock, par value $.001 per share (the “Series B-1 Stock”, and collectively with the Series B Stock, the “Series B Preferred
Stock”), and three million eight hundred fifty five thousand one hundred eighty (3,855,180) shares of the Company’s Series C Convertible Preferred Stock, par value $.00l per share (the “Series C
Stock”); 
 WHEREAS, certain of the Investors have heretofore entered into a Fourth Amended
and Restated Stock Restriction and Co-Sale Agreement, dated as of May 22, 2006 (together with all exhibits thereto, the “Prior Agreement”), in connection with a certain Series C Convertible Stock Purchase Agreement dated
as of May 22, 2006, by and among certain of the Investors and the Company pursuant to which the Company issued the Series C Stock to such Investors; 
 WHEREAS, the Company has agreed to issue to certain Investors up to an aggregate of eight million eight thousand eight hundred forty two (8,008,842) shares of the Company’s Series D
Convertible Preferred Stock, par value $.001 per share (the “Series D 

  
 Page 1 of 33

 Stock”, and collectively with the Series A Preferred Stock, the Series B Preferred Stock
and the Series C Stock, the “Convertible Preferred Stock”), pursuant to a certain Series D Convertible Preferred Stock Purchase Agreement dated as of the date hereof, by and among certain of the Investors and the Company (the
“Purchase Agreement”); and 
   WHEREAS, the Company, the Holders and
the Investors have mutually agreed to amend and restate the Prior Agreement in its entirety. 
 NOW,
THEREFORE, for good and valuable consideration, the receipt and legal sufficiency of which is hereby acknowledged, the Company, the Holders and the Investors hereby agree to amend and restate the Prior Agreement in its entirety as follows:

 1.        Prohibited Transfers. The Holders shall not sell,
assign, transfer, pledge, hypothecate, mortgage or dispose of, by gift or otherwise, or in any way encumber, all or any part of the Shares (as hereinafter defined) owned by them except in compliance with the terms of this Agreement. For purposes of
this Agreement, the term “Shares” shall mean and include all shares of Common Stock (excluding shares of Common Stock issued upon conversion of the Convertible Preferred Stock) and the Warrants to purchase shares of Common Stock issued or
issuable pursuant to the terms of the Interactive Marketing Agreement between the Company and America Online, Inc. dated as of November 10, 2004 (the “Purchaser Warrants”). The Company shall not transfer on its books any
Shares which are subject to this Agreement unless the provisions hereof have been complied with in full. Any purported transfer by a Holder of Shares without full compliance with the provisions of this Agreement shall be null and void. 

2.        Right of First Refusal on Dispositions by the Holders. If at any
time any Holder wishes to sell, assign, transfer or otherwise dispose of any or all Shares owned by such Holder pursuant to the terms of a bona fide offer received from a third party, such Holder shall submit a written offer to sell such Shares to
the Company and the Investors on terms and conditions, including price, not less favorable to the Company and the Investors than those on which such Holder proposes to sell such Shares to such third party (the “Offer”). The
Offer shall disclose the identity of the proposed purchaser or transferee, the Shares proposed to be sold or transferred (the “Offered Shares”), the agreed terms of the sale or transfer, including price, and any other
material facts relating to the sale or transfer. The Investors shall, subject to the first sentence of Section 3, have the right to purchase, on the same terms and conditions set forth in the Offer, that portion of the Offered Shares to be
determined in the manner set forth herein. Each Investor shall have the right to purchase up to that number of Offered Shares as shall be equal to the aggregate Offered Shares multiplied by a fraction, the numerator of which is the number of shares
of Common Stock issued or issuable to such Investor upon the conversion of all shares of Convertible Preferred Stock held by such Investor together with the number of shares of Common Stock actually issued upon the exercise of Purchaser Warrants and
held by such Investor (the “Conversion Shares”) and the denominator of which is the aggregate number of Conversion Shares held by all Investors. The number of Offered Shares each Investor or Qualified Transferee, as that term
is defined below, is entitled to purchase under this Section 2 shall be referred to as such Investor’s “Pro Rata Fraction.” Each Investor shall have the right to transfer its right to any Pro Rata Fraction or part thereof to any
Qualified Transferee (as defined below). In the event an Investor does not wish to purchase or to transfer its right to purchase its Pro Rata Fraction, then any Investors who so elect shall have the right to purchase, on a pro rata

  
 Page 2 of 33

 
basis with any other Investors who so elect, any Pro Rata Fraction not purchased by an Investor or Qualified Transferee. Each Investor shall act upon the Offer as soon as practicable after
receipt of the Offer, and in all events within fifteen (15) days after receipt of the Offer. Each Investor shall have the right to accept the Offer as to all or part of the Offered Shares. In the event that an Investor shall elect to purchase
all or part of the Offered Shares covered by the Offer, said Investor shall individually communicate in writing such election to purchase to whichever of the Holders has made the Offer, which communication shall be delivered in accordance with
Section 8 below and shall, when taken in conjunction with the Offer be deemed to constitute a valid, legally binding and enforceable agreement for the sale and purchase of the Offered Shares covered thereby. 

If the Investors do not exercise their right to purchase all of the Offered Shares from a Holder within said fifteen-day
period, such Holder shall promptly notify the Company in writing (the “Company Notice”) as to the number of Offered Shares which the Investors shall not have agreed to purchase (the “Remaining
Shares”). Subject to the approval of the holders of at least fifty eight percent (58%) of the votes attributable to all outstanding shares of Convertible Preferred Stock (voting as a separate class on an as-converted to Common
Stock basis) (the “Requisite Investors”), the Company shall have the right to purchase all of the Remaining Shares on the same terms and conditions as set forth in the Offer. If the Company elects to purchase any Remaining
Shares, it shall notify the Holder within fifteen days after receipt of the Company Notice (the “Final Date”). 
 For purposes of this Section 2, a “Qualified Transferee” of an Investor shall mean any person (i) who is an Investor, (ii) who is an “affiliated person” of an Investor,
as that term is defined in the Investment Company Act of 1940, (iii) who is a partner of an Investor, or (iv) who previously acquired at least 250,000 shares of Convertible Preferred Stock (as adjusted for stock splits, stock dividends,
reclassifications, recapitalizations or other similar events). 

3.          Right of Participation in Sales by Holders. In the
event that the Investors and the Company do not exercise their rights under Section 2 with respect to all of the Offered Shares, the transferring Holder may, subject to the provisions of this Section 3, sell, assign, transfer or otherwise
dispose of all of the Offered Shares to the third party named in the Offer (the “Purchaser”). Before any such sale, assignment, transfer or other disposition, each Investor shall have the right to require, as a condition to
such sale or disposition, that the Purchaser purchase from said Investor at the same price per Share (which shall be calculated on a Common Stock equivalent basis if the Stock (as defined in Section 5) to be sold by an Investor is of a
different class or series of stock from that of the Shares) and on the same terms and conditions as involved in such sale or disposition by the Holder up to a number of shares of Stock as is equal to the product of (x) the number of Shares
proposed to be sold by the Holder, times (y) a fraction, the numerator of which is the number of Conversion Shares held by such Investor and the denominator of which is the aggregate number of Conversion Shares held by all Investors electing to
participate in the sale pursuant to this Section 3 plus the number of shares of Stock owned by the selling Holder (calculated on an as-converted to Common Stock basis). Each Investor wishing so to participate in any such sale or disposition
shall notify the selling Holder of such intention as soon as practicable after receipt of the Offer made pursuant to Section 2, and in all events within fifteen (15) days after receipt of the Investor Notice. In the event that an

  
 Page 3 of 33

 
Investor shall elect to participate in such sale or disposition, said Investor shall individually communicate such election to the selling Holder, which communication shall be delivered in
accordance with Section 8 below. The Holder and/or each participating Investor shall sell to the Purchaser all, or at the option of the Purchaser, any part of the Stock proposed to be sold by them at not less than the price and upon other terms
and conditions, if any, not more favorable to the Purchaser than those originally offered; provided, however, that any purchase of less than all of such Stock by the Purchaser shall be made from the Holder and/or each participating Investor
pro rata based on the number of shares such Holder and/or Investors would otherwise be entitled to sell to such Purchaser pursuant to this Section 3. The selling Holder or Investor shall use his or its reasonable best efforts to obtain the
agreement of the Purchaser to the participation of the participating Investors in the contemplated sale, and shall not sell any Stock to such Purchaser if such Purchaser declines to permit the participating Investors to participate pursuant to the
terms of this Section 3. The provisions of this Section 3 shall not apply to the sale of any Shares by a Holder to an Investor pursuant to an Offer under Section 2. 

4.         Permitted Transfers. 

(i)        Anything herein to the contrary notwithstanding, the provisions of
Sections 1, 2 and 3 shall not apply to: (a) any transfer of Shares by a Holder by gift or bequest or through inheritance to, or for the benefit of, any member or members of his or her immediate family (which shall include any spouse, children
or grandchildren) or to a trust, partnership or limited liability company for the benefit of such Holder or such members of his or her immediate family; (b) any transfer of Shares by a Holder to a trust in respect of which he or she serves as
trustee, provided that the trust instrument governing said trust shall provide that such Holder, as trustee, shall retain sole and exclusive control over the voting and disposition of said Shares until the termination of this Agreement; (c) any
sale of Common Stock in a public offering pursuant to a registration statement filed by the Company with the Securities and Exchange Commission; (d) any repurchase of shares of Common Stock by the Company from officers, employees, directors or
consultants of the Company which are subject to restrictive stock purchase agreements under which the Company has the option to repurchase such shares at cost (or a lesser amount) upon the occurrence of certain events; and (e) any repurchase of
Shares by the Company pursuant to the Restricted Stock Agreement, dated as of March 2, 2004, by and between the Company and Daniel Stephen Hafner, and the Restricted Stock Agreement, dated as of March 2, 2004, by and between the Company
and Paul English (collectively, the “Founder Stock Agreements”). 

(ii)        In the event of any such transfer, other than pursuant to subsections
(i)(c), (d) and (e) of this Section 4, the transferee of the Shares shall hold the Shares so acquired with all the rights conferred by, and subject to all the restrictions imposed by, this Agreement, and as a condition to such
transfer, each such transferee shall execute and deliver an Instrument of Accession in the form of Schedule II agreeing to be bound by the provisions of this Agreement. 

5.          Election of Directors. 

(a)        Board Designation Rights; Initial Members. Each Stockholder
hereby agrees to vote all of the Stock of the Company now owned or hereafter acquired by such party (and attend, 

  
 Page 4 of 33

 
in person or by proxy, all meetings of stockholders called for the purpose of electing directors), and agree to take all actions (including, but not limited, to the nomination of specified
persons, the execution of written consents and the calling of a stockholder meeting for the purpose of electing such specified persons) to cause and maintain the election to the Board of Directors of the Company, to the extent permitted pursuant to
the Company’s Amended and Restated Certificate of Incorporation, as amended from time to time (the “Certificate of Incorporation”), the following: 

(i)        the then current Chief Executive Officer of the Company as one
(1) of the Common Directors (as defined in the Certificate of Incorporation), who shall initially be Daniel Stephen Hafner; 
 (ii)        one (1) person designated by the holders of a majority of the outstanding shares of Common Stock, voting as a separate class, as the other Common
Director, who shall initially be Paul English; 
 (iii)        two
(2) persons designated by the holders of at least seventy percent (70%) of the outstanding shares of the Series A Preferred Stock, voting as a separate class on an as-converted to Common Stock basis (the “Series A
Designators”), as the two Series A Directors (as defined in the Certificate of Incorporation), who shall initially be Joel Cutler and Terrell Jones; 

(iv)        one (1) person designated by the holders of at least a majority
of the outstanding shares of the Series C Stock, voting as a separate class (the “Series C Designators”), as the Series C Director (as defined in the Certificate of Incorporation), who shall initially be Hendrik Nelis;

 (v)        for so long as Sequoia Capital Growth Fund III or one or
more of its affiliates (as defined in Rule 501 of Regulation D under the Securities Act of 1933, as amended) (“Sequoia”) holds at least 1,000,000 shares of the Company’s Preferred Stock (as adjusted from time to time to reflect any
stock split, stock dividend, reverse stock split or similar event affecting the Preferred Stock), one (1) person designated by Sequoia as the Series D Director (as defined in the Certificate of Incorporation), who shall initially be Michael
Moritz. In the event Sequoia does not hold at least 1,000,000 shares of the Company’s Preferred Stock (as adjusted from time to time to reflect any stock split, stock dividend, reverse stock split or similar event affecting the Preferred
Stock), then, in lieu of Sequoia, the holders of at least a majority of the outstanding shares of the Series D Stock, voting as a separate class, shall be entitled to designate one (1) person as the Series D Director. The individual, entity, or
group of individuals and/or entities who has the right to designate the Series D Director pursuant this Section 5(a)(v) shall be referred to herein as the “Series D Designator”; and 

(vi)        one (1) person designated jointly by the Series A Designators,
the Series C Designators, and the Series D Designator, each voting as a separate series, as the Remaining Director (as defined in the Certificate of Incorporation), who shall initially be Greg Slyngstad. 

  
 Page 5 of 33

  
 For the purposes of
this Agreement, (x) “Stock” shall mean and include all Convertible Preferred Stock and all shares of Common Stock, and all other securities of the Company which may be exchangeable for, convertible into or issued in exchange for or in
respect of shares of Common Stock (whether by way of stock split, stock dividends, combination, reclassification, reorganization or any other means), (y) “Board Designee” shall mean any individual who is designated for election to the
Company’s Board of Directors pursuant to this Section 5; and (z) “Designator” or “Designators” shall mean, as applicable, any individual, entity, or group of individuals and/or entities who has the right to
designate one (1) or more Board Designees for election to the Company’s Board of Directors pursuant to this Section 5. 
 (b)        Removal; Successor Directors. In the absence of any designation from the appropriate Designator or Designators, the Board Designee previously
designated by them and then serving shall be reelected if still eligible to serve as provided herein. From time to time during the term of this Agreement, a Designator or Designators may, in their sole discretion: 

(i)        elect to initiate the removal from the Company’s Board of Directors of any
incumbent Board Designee who occupies a board seat for which such Designator or Designators are entitled to designate the Board Designee under Section 5(a), and/or 
 (ii)        designate a new Board Designee for election to a board seat for which such Designator or Designators are entitled to designate the Board Designee under
Section 5(a) (whether to replace a prior Board Designee or to fill a vacancy in such board seat); provided, however, that any new Board Designee designated by the Series A Designators, the Series C Designators and the Series D Designator
for the Remaining Director must be ratified by the holders of a majority of the outstanding shares of Common Stock, which ratification may not be unreasonably withheld or delayed; provided further, however, no such ratification is required
for any new Board Designee who has general experience with marketing and the travel related ecommerce industry (including Greg Slyngstad). 
 In the event of an initiation of removal of a Board Designee pursuant to Section 5(b)(i), the Stockholders shall vote all of the Stock of the Company now owned or hereafter acquired by them (and
attend, in person or by proxy, all meetings of stockholders called for the purpose of electing directors),. and agree to take all actions to cause the removal from the Company’s Board of Directors of the Board Designee or Designees so
designated for removal by the appropriate Designator or Designators; provided, however, in no event shall any party vote to remove any Board Designee unless the appropriate Designator or Designators have so directed pursuant to
Section 5(b)(i). In the event of designation of a Board Designee pursuant to Section 5(b)(ii), the parties shall vote all of the Stock of the Company now owned or hereafter acquired by them (and attend, in person or by proxy, all meetings
of stockholders called for the purpose of electing directors), and agree to take all actions to cause the election to the Company’s Board of Directors of any new Board Designee or Designees so designated for election to the Company’s Board
of Directors pursuant to Section 5(b)(ii). 
 Without the consent of the Requisite Investors, the parties hereby agree that
they will not take any action, by vote or otherwise, to increase the authorized number of directors constituting the Company’s Board of Directors to more than seven (7) directors, unless the holders of

  
 Page 6 of 33

 
Convertible Preferred Stock are then entitled to elect, in addition to the two (2) Series A Directors described in Section 5(a)(iii) above and one Series C Director described in
Section 5(a)(iv) above, two additional Series A Directors and one additional Series C Director pursuant to Article 4B, subparagraph 6C of the Certificate of Incorporation (the “Additional Directors”), in which case the
Company’s Board of Directors shall consist of no more than ten (10) members. If and for so long as the holders of Convertible Preferred Stock are entitled to elect the Additional Directors pursuant to Article 4B, subparagraph 6C of the
Certificate of Incorporation, each of the parties hereto hereby agrees to vote all of the Stock of the Company now owned or hereafter acquired in favor of the election to the Board of Directors of two (2) persons designated from time to time by
the Series A Designators and one (1) person designated from time to time by the Series C Designators. 

(c)        Observer Rights. Oak Investment Partners XII, Limited
Partnership shall be entitled to have a representative (the “Oak Board Observer”) attend all meetings of the Company’s Board of Directors and all committees thereof in a nonvoting capacity (subject to the Company’s
determination upon the advice of counsel that the Oak Board Observer’s presence may violate attorney-client privilege or would otherwise be excused from a meeting were the Oak Board Observer a director) and, in this respect, the Company shall
give the Oak Board Observer copies of all notices, minutes, consents and other materials that it provides to its directors. The Oak Board Observer may participate in discussions of matters brought to the Company’s Board of Directors. As a
condition to attending such meetings and receiving such materials, the Oak Board Observer will agree in writing to hold in confidence and trust and not use or disclose any confidential information provided to or learned by it in connection with its
rights under this paragraph as if the Oak Board Observer were a member of the Company’s Board of Directors. 
 6.        Drag-Along Rights. If(a) a majority of the members of the Company’s Board of Directors and (b) the Requisite Investors approve a sale of
Company or all or substantially all of Company’s assets, whether by means of a merger, consolidation, sale of stock or assets or otherwise (a “Sale of the Company”), all Investors and Holders shall consent to and vote
their Shares in favor of the Sale of the Company, and if the Sale of the Company is structured as (i) a merger or consolidation of the Company, or a sale of all or substantially all of the Company’s assets, each Investor and Holder shall
waive any dissenters’ rights, appraisal rights or similar rights in connection with such merger, consolidation or asset sale, or (ii) a sale of the stock of the Company, the Investors and Holders shall agree to sell their Shares on the
terms and conditions approved by (x) a majority of the members of the Company’s Board of Directors and (y) the Requisite Investors; provided, however, that, (A) all proceeds from such Sale of the Company shall be payable to the
holders of the Company’s Stock in accordance with the Certificate of Incorporation, including, without limitation, Article 4B, Paragraph 3 thereof, which entitles the holders of Convertible Preferred Stock to a liquidation preference payment
and other rights set forth therein, except that, at the discretion of the Company’s Board of Directors, holders of shares of Common Stock that are unvested on the date that the Sale of the Company is consummated may receive, in lieu of proceeds
from the Sale of the Company and in exchange for their unvested shares of Common Stock, unvested securities or options to acquire securities of the entity surviving the Sale of the Company on an equitable basis, (B) except as set forth in the
preceding clause (A), the terms of such Sale of the Company applicable to holders of shares 

  
 Page 7 of 33

 
of each series of Convertible Preferred Stock, in their capacities as holders thereof, shall be no less favorable than the terms applicable to the holders of all other series of Convertible
Preferred Stock in their capacities as holders thereof and (C) if the Requisite Investors are given the option to choose the form of consideration to be received in such Sale of the Company on its Stock, the obligations of a Holder or other
Investor to approve the Sale of the Company under this Section 6 shall be conditioned upon it having received the same option. Each Holder and Investor hereby irrevocably constitutes and appoints the Company and any representative or agent
thereof, with full power of substitution, as its true and lawful attorney-in-fact with full irrevocable power and authority in the place and stead of such Holder or Investor and in the name of such Holder or Investor or in its own name, for the
purpose of carrying out the terms of this Section 6, to take any and all appropriate action and to execute any and all documents and instruments which may be necessary or desirable to accomplish the purposes of this Section 6. Such Holder
and Investor hereby ratifies all that said attorneys shall lawfully do or cause to be done by virtue hereof. 

7.        Termination. This Agreement, and the respective rights and
obligations of the parties hereto, shall terminate upon the completion of a firm commitment underwritten public offering of Common Stock in which (a) the aggregate gross proceeds received by the Company shall be at least $25,000,000, and
(b) the per share price paid by the public for such shares shall be at least $31.09 (appropriately adjusted to reflect any subdivision or combination of the Common Stock occurring after the date hereof) (a “Qualified Public
Offering”); provided, however, that Sections 1 through 3 shall terminate on the earlier of (i) the completion of a Qualified Public Offering and (ii) ten (10) years after the date hereof. 

8.        Notices. Any notices or other communication required to be sent
or given hereunder by any of the parties shall in every case be in writing and shall be deemed properly served if(a) delivered personally, (b) sent by certified U.S. Mail, with first class postage prepaid, return receipt requested,
(c) delivered by a recognized overnight courier service, with certification of receipt requested, or (d) sent by facsimile transmission with a confirmation copy sent by overnight courier, in each case, to the parties at the addresses and
telecopy numbers as set forth below or at such other addresses or telecopy number as may be furnished in writing by any party pursuant to this Section 8 (except .that notices of changes of address or a telecopy number shall only be effective
upon receipt): 
 if to the Company or any other party hereto that is also a party to the Purchase Agreement, at
the address of such party set forth in the Purchase Agreement, with a copy sent to such party’s legal counsel designated in the Purchase Agreement, if applicable; 

if to any other party hereto as of the date of the Agreement, to such party at its address set forth on Schedule I
hereto; 
 if to a Holder who subsequently becomes a party to this Agreement, at its address set forth on the
Instrument of Accession pursuant to which such Holder became a party to this Agreement; and 

  
 Page 8 of 33

  
 if to
an Investor who subsequently becomes a party to this Agreement, at its address set forth on the Instrument of Accession pursuant to which such Investor became a party to this Agreement. 
 Date of service of such notice shall be (w) the date such notice is personally delivered, (x) three (3) days after the date of mailing if sent by certified mail, (y) two (2) days
after date of delivery to the overnight courier if sent by overnight courier (as evidenced by a written receipt from the courier), or (z) the next succeeding business day after transmission by facsimile. 

9.        Failure to Deliver Shares. If a Holder becomes obligated to sell
any Shares owned by, or held for the benefit of, such Holder to an Investor or a Qualified Transferee under this Agreement and fails to deliver such Shares in accordance with the terms of this Agreement, such Investor may, at its option, in addition
to all other remedies it may have, send to the Company for the benefit of such Holder the purchase price for such Shares as is herein specified. Thereupon, the Company upon written notice to said Holder, (a) shall cancel on its books the
certificate(s) representing the Shares to be sold and (b) shall issue, in lieu thereof, in the name of such Investor, a new certificate(s) representing such Shares, and thereupon all of said Holder’s rights in and to such shares shall
terminate. The Company may exercise a similar remedy in enforcing its rights under Section 2. If a Holder transfers any Shares to a Purchaser in violation of this Agreement, the Company may, at the election of a majority of the disinterested
members of the Company’s Board of Directors, cancel on the books of the Company any shares of capital stock then held by such Holder, and any such breaching Holder agrees to purchase from the Purchasers and any transferee a number of shares of
capital stock equal to the amount so transferred in violation of this Agreement. 

10.        Specific Performance Proxy. The rights of the parties under
this Agreement are unique and, accordingly, the parties shall, in addition to such other remedies as may be available to any of them at law or in equity, have the right to enforce their rights hereunder by actions for specific performance to the
extent permitted by law. The voting of shares of capital stock pursuant to this Agreement may be effected in person, by proxy, by written consent or in any other manner permitted by applicable law. Each Stockholder hereby grants to the Secretary of
the Company, in the event that such Stockholder fails to vote its shares of capital stock as required by this Agreement, a proxy coupled with an interest in all shares of capital stock owned by such Stockholder empowering the Secretary to vote such
shares as to such matters as are set forth in Section 5 hereof, which proxy is irrevocable until this Agreement terminates pursuant to its terms or this Section 10 is amended to remove such grant of proxy in accordance with Section 14
of this Agreement. 
 11.        Legend. The certificates
representing the Shares shall bear on their face a legend indicating the existence of the restrictions imposed hereby. 
 12.        Entire Agreement. This Agreement, the Founder Stock Agreements and the Purchase Agreement (including any and all exhibits, schedules and other
instruments contemplated thereby) constitute the entire agreement among the parties with respect to the subject matter hereof and supersede all prior agreements or understandings between them or any of them as to such subject matter. 

  
 Page 9 of 33

  

13.        Waivers and Further Agreements. Except as provided in
Section 14, any of the provisions of this Agreement may be waived by an instrument in writing executed and delivered by Requisite Investors. Any waiver by any party of a breach of any provision of this Agreement shall not operate or be
construed as a waiver of any subsequent breach of that provision or of any other provision hereof. Each of the parties hereto agrees to execute all such further instruments and documents and to take all such further action as any other party may
reasonably require in order to effectuate the terms and purposes of this Agreement. Notwithstanding the foregoing, no waiver may treat one Investor more adversely than any other Investor without the consent of such Investor adversely affected by
such waiver. 
 14.        Amendments. Except as otherwise
expressly provided herein, this Agreement may not be amended except by an instrument in writing executed by (i) the Company and (ii) the Requisite Investors. Notwithstanding the foregoing, (i) the consent of the Holders holding a
majority of the outstanding shares of Common Stock subject to this Agreement shall be required for any amendment that materially adversely affects the rights of the Holders, (ii) no amendment may treat one Investor more adversely than any other
Investor without the consent of such Investor adversely affected by such amendment, (iii) no amendment may treat one Holder more adversely than any other Holder without the consent of such Holder, and (iv) no amendment, waiver or
modification to the rights of a Designator to appoint or remove a Board Designee pursuant to Section 5 shall be effective without the consent of such Designator. 

15.        Assignment Successors and Assigns. This Agreement shall be
binding upon and shall inure to the benefit of the parties hereto and their respective heirs, executors, legal representatives, successors and permitted transferees, except as may be expressly provided otherwise herein. 

16.        Severability. In case any one or more of the provisions
contained in this Agreement shall for any reason be held to be invalid, illegal or unenforceable in any respect, such invalidity, illegality or unenforceability shall not affect any other provision of this Agreement and such invalid, illegal and
unenforceable provision shall be reformed and construed so that it will be valid, legal, and enforceable to the maximum extent permitted by law. 
 17.        Counterparts. This Agreement may be executed in two or more counterparts, each of which shall be deemed an original, but all of which together
shall constitute one and the same instrument. 
 18.        Section
Headings. The headings contained in this Agreement are for reference purposes only and shall not in any way affect the meaning or interpretation of this Agreement. 

19.        Governing Law. This Agreement shall be construed and enforced
in accordance with and governed by the laws of the General Corporation Law of the State of Delaware as to matters within the scope thereof, and as to all other matters shall be governed by and construed in accordance with the internal laws of the
Commonwealth of Massachusetts, without regard to its principles of conflicts of laws. 

  
 Page 10 of 33

  

20.        Additional Parties. Any purchaser of Convertible Preferred Stock
pursuant to the Purchase Agreement shall become a party to this Agreement by executing and delivering to the Company an executed Instrument of Accession in the form of Schedule II hereto. Upon such execution and delivery, such purchaser shall
be deemed to be an “Investor” hereunder with all of the rights and obligations thereof. Unless otherwise consented to by the Board of Directors, the Company shall cause each officer, director, employee, consultant or other service provider
of the Company who acquires shares of Common Stock representing greater than 1% of the fully- diluted capital stock of the Company or options to purchase such number of shares of Common Stock, to become a party to this agreement by executing and
delivering to the Company an executed Instrument of Accession in the form of Schedule II hereto. Upon such execution and delivery, such holder shall be deemed to be a “Holder” hereunder with all of the rights and obligations
thereof. 
 [signature pages follow] 

  
 Page 11 of 33

  
 IN
WITNESS WHEREOF, the undersigned have executed this Fifth Amended and Restated Stock Restriction and Co-Sale Agreement as a sealed instrument as of the day and year first above written. 
 COMPANY: 
 KAYAK SOFTWARE CORPORATION 

 

			
	By:	 	         /s/ Steve
Hafner

			
	Name:	 	                 Steve
Hafner

			
	Title:	 	
                    
      CEO

 [The remainder of this page is intentionally left blank.]

 Signature Page to Co-Sale Agreement 

  
 HOLDERS: 

 

	
	 /s/ Daniel Stephen Hafner

	Daniel Stephen Hafner

  

	
	 /s/ Paul English

	Paul English

 McKane 2007 Grandchildren Trust 

 

			
	By:    	 	       /s/ Steve
Hafner

			
	Name:	 	           Steve Hafner

	Title:	 	

 J.M. Hafner Trust 
  

			
	By:    	 	       /s/ Steve
Hafner

			
	Name:	 	           Steve Hafner

	Title:	 	

 Joseph A. Hafner Trust 
  

			
	By:    	 	       /s/ Steve
Hafner

			
	Name:	 	           Steve Hafner

	Title:	 	

 Merrill T. Hafner Trust 
  

			
	By:    	 	       /s/ Steve
Hafner

			
	Name:	 	           Steve Hafner

	Title:	 	

 D.S. Hafner Trust 
  

			
	By:    	 	       /s/ Steve
Hafner

			
	Name:	 	           Steve Hafner

	Title:	 	

 Signature Page to Co-Sale Agreement 

  
 The Paul M. English 2007 Irrevocable
Family Trust 
  

			
	By:	 	     /s/ Paul M.
English

			
	Name:	 	Paul M. English, Trustee

  

			
	By:	 	  

			
	Name:	 	Jean A. English, Trustee

 The Paul M. English 2006
Irrevocable Family Trust 
  

			
	By:	 	     /s/ Paul M.
English

			
	Name:	 	Paul M. English, Trustee

  

			
	By:	 	  

			
	Name:	 	Jean A. English, Trustee

 Signature Page to
Co-Sale Agreement 

  
 AMERICA ONLINE, INC. 

 

			
	By:	 	  

			
	Name:	 	
	Title:	 	

 Signature Page to Co-Sale Agreement 

  
 INVESTORS: 

 

									
	GENERAL CATALYST GROUP II, L.P.	  		 	GENERAL CATALYST GROUP III, L.P.
					
	By:	  	General Catalyst Partners II, L.P.	  		 	By:	 	General Catalyst Partners III, L.P.
	Its General Partner	  		 	Its General Partner
					
	By:	  	General Catalyst GP II, LLC	  		 	By:	 	General Catalyst GP III, LLC
	Its General Partner	  		 	Its General Partner
					
	By:	  	 /s/ William J. Fitzgerald
	  		 	By:	 	 /s/ William J. Fitzgerald

									
	Name:	  	William J. Fitzgerald	  		 	Name:	 	William J. Fitzgerald

									
	Title:	  	Member and Chief Financial Officer	  		 	Title:	 	Member and Chief Financial Officer

									
			
	GC ENTREPRENEURS FUND II, L.P.	  		 	GC ENTREPRENEURS FUND III, L.P.

									
					
	By:	  	General Catalyst Partners II, L.P.	  		 	By:	 	General Catalyst Partners III, L.P.

									
	Its General Partner	  		 	Its General Partner

									
					
	By:	  	General Catalyst GP II, LLC	  		 	By:	 	General Catalyst GP III, LLC

									
	Its General Partner	  		 	Its General Partner

									
					
	By:	  	 /s/ William J. Fitzgerald
	  		 	By:	 	 /s/ William J. Fitzgerald

									
	Name:	  	William J. Fitzgerald	  		 	Name:	 	William J. Fitzgerald

									
	Title:	  	Member and Chief Financial Officer	  		 	Title:	 	Member and Chief Financial Officer

									
			
	GENERAL CATALYST GROUP V, L.P.	  		 	    GC ENTREPRENEURS FUND V, L.P.

									
					
	By:	  	General Catalyst Partners V, L.P.	  		 	By:	 	General Catalyst Partners V, L.P.

									
	Its General Partner	  		 	Its General Partner

									
					
	By:	  	General Catalyst GP V, LLC	  		 	By:	 	General Catalyst GP V, LLC

									
	Its General Partner	  		 	Its General Partner

									
					
	By:	  	 /s/ William J. Fitzgerald
	  		 	By:	 	 /s/ William J. Fitzgerald

									
	Name:	  	William J. Fitzgerald	  		 	Name:	 	William J. Fitzgerald
	Title:	  	Member and Chief Financial Officer	  		 	Title:     Member and Chief Financial Officer

 Signature Page to Co-Sale Agreement 

  

			
	GENERAL CATALYST GROUP V SUPPLEMENTAL, L.P.
		
	By:	 	General Catalyst Partners V, L.P.
	Its General Partner
		
	By:	 	General Catalyst GP V, LLC
	Its General Partner
		
	By:	 	 /s/ William J. Fitzgerald

			
	Name:	 	William J. Fitzgerald

			
	Title:	 	Member and Chief Financial Officer

Signature Page to Co-Sale Agreement 

  

	
	 /s/ Daniel Stephen Hafner

	Daniel Stephen Hafner

 Signature Page to
Co-Sale Agreement 

  

	
	 /s/ Paul English

	Paul English

 Signature Page to Co-Sale
Agreement 

  
 AMERICA ONLINE, INC. 

 

			
	By:	 	  

			
	Name:	 	
	Title:	 	

 Signature Page to Co-Sale Agreement 

  
 ACCEL PARTNERS 

 

					
	By:	 	Accel London II Associates L.P.
	Its:	 	General Partner
		
	By:	 	Accel London II Associates L.L.C.
	Its:	 	General Partner
		
	By:	 	 /s/ Jonathan Biggs

		 	Name:	 	Jonathan Biggs
		 	Title:	 	Attorney in Fact
	
	ACCEL LONDON INVESTORS 2006 L.P.
		
	By:	 	Accel London II Associates L.L.C.
	Its:	 	General Partner
		
	By:	 	 /s/ Jonathan Biggs

		 	Name:      	 	Jonathan Biggs
		 	Title:	 	Attorney in Fact

 Signature Page to Co-Sale
Agreement 

  

	
	  

	Greg Slyngstad

 Signature Page to Co-Sale
Agreement 

  

			
	SEQUOIA CAPITAL XI
	SEQUOIA TECHNOLOGY PARTNERS XI
	SEQUOIA CAPITAL XI PRINCIPALS
	FUND
		
	By:	 	SC XI Management, LLC
	A Delaware Limited Liability Company
	General Partner of Each
		
	By:	 	 (illegible)

			
	Name:	 	

			
	Title:	 	Managing Member

  

			
	SEQUOIA CAPITAL GROWTH FUND III
	SEQUOIA CAPITAL GROWTH PARTNERS III
	SEQUOIA CAPITAL GROWTH III PRINCIPALS FUND

			
		
	By:	 	SCGF III Management, LLC
	A Delaware Limited Liability Company
	General Partner of Each
		
	By:	 	 (illegible)

			
	Name:	 	
	Title:	 	Managing Member

 Signature Page to Co-Sale
Agreement 

  

	
	TRIDENT CAPITAL FUND-V, L.P
	TRIDENT CAPITAL FUND-V AFFILIATES FUND, L.P.
	TRIDENT CAPITAL FUND-V AFFILIATES FUND (Q), L.P.
	TRIDENT CAPITAL FUND-V PRINCIPALS FUND, L.P.
	TRIDENT CAPITAL PARALLEL FUND-V, C.V.
	
	 Executed on behalf of the foregoing funds
 by the undersigned, as an authorized signatory
 of the respective general partner of each such
fund:

  

			
	 (illegible)
	 	
	  (signature)	 	
		
	 (illegible)
	 	
	  (print name)	 	

 Signature Page to Co-Sale Agreement 

  

									
	NORWEST VENTURE PARTNERS VII-A, LP	  		  	NORWEST VENTURE PARTNERS X, LP
					
	By:	 	Itasca VC Partners VII-A, LLC	  		  	By:	 	Genesis VC Partners X, LLC
	Its General Partner	  		  	Its General Partner
					
	By:	 	  (illegible)
	  		  	By:	 	   (illegible)

	Name:	 	  
	  		  	Name:	 	  

	Title:	 	  
	  		  	Title:	 	  

 Signature Page to Co-Sale Agreement 

  

			
	OAK INVESTMENT PARTNERS XII, LIMITED PARTNERSHIP
		
	By:	  	Oak Associates XII, LLC, its General Partner

  

					
	By:	 	 /s/ Iftikar A. Ahmed
	  	
	Name:	 	    Iftikar A. Ahmed	  	
	Title:	 	 Managing Member	  	

 Signature Page to Co-Sale Agreement 

  

							
	LEHMAN BROTHERS VENTURE PARTNERS V L.P.
	By:	  	Lehman Brothers Venture Associates V L.P., its General Partner
	By:	  	Lehman Brothers Venture Associates V LLC, its General Partner
	By:	  	             /s/ JAMES D.
HINSON
	  		  	
	Name:	  	     JAMES D. HINSON
	  		  	
	Tit1e:	  	             Vice
President
	  		  	

  

							
	LEHMAN BROTHERS VENTURE PARTNERS V-P, L.P.
	By:	  	Lehman Brothers Venture Associates V L.P., its General Partner
	By:	  	Lehman Brothers Venture Associates V LLC, its General Partner
	By:	  	             /s/ JAMES D.
HINSON
	  		  	
	Name:	  	     JAMES D. HINSON
	  		  	
	Tit1e:	  	             Vice
President
	  		  	

  

							
	LB I Group Inc.	  		  	
	By:	  	             /s/ JAMES D.
HINSON
	  		  	
	Name:	  	     JAMES D. HINSON
	  		  	
	Tit1e:	  	             Vice
President
	  		  	

 Signature Page to Co-Sale Agreement 

  
 GOLD HILL VENTURE LENDING 03, L.P.

  

					
	By:	  	 /s/ J F Tower
	  	
	Name:	  	        J F Tower	  	
	Title:	  	        Partner	  	

 Signature Page to Co-Sale Agreement 

  
 SCHEDULE I

 KAYAK SOFTWARE CORPORATION 
 SCHEDULE OF HOLDERS AND INVESTORS 
 Investors: 

General Catalyst Group II, L.P. 
 GC
Entrepreneurs Fund II, L.P. 
 General Catalyst Group III, L.P. 
 GC Entrepreneurs Fund III, L.P. 
 General Catalyst Group V, L.P. 

General Catalyst Group V Supplemental, L.P. 
 GC
Entrepreneurs Fund V, L.P. 
 20 University Road, Suite 450 
 Cambridge, MA 02138 
 Fax: (617) 234-7040 

Attn: Joel Cutler 
 Daniel Stephen Hafner

 2347 Bronson Road 
 Fairfield, CT
06824 
 Fax: (203) 899-3125 

Paul English 
 10 Samoset Road 

Winchester, MA 01890 
 Greg Slyngstad

 24733 SE Windsor Blvd 
 Sammamish, WA
98074 
 America Online, Inc. 
 22000
AOL Way 
 Dulles, VA 20166 
 Attn:
Deputy General Counsel 
 Fax: (703) 265-1105 

  
 Sequoia Capital Growth Fund III

 Sequoia Capital Growth Partners III 

Sequoia Capital Growth III Principals Fund 

Sequoia Capital XI 
 Sequoia Technology Partners
XI 
 Sequoia Capital XI Principals Fund 

3000 Sand Hill Road 
 Bldg 4, Suite 180

 Menlo Park, CA 94025 
 Accel London
II, L.P. 
 Accel London Investors 2006 L.P. 
 428 University Avenue 
 Palo Alto, CA 94301-1812 

Fax: (650) 614-4880 
 Attn: Richard Zamboldi

 Notices also sent to 
 16 St.
James’s Street 
 London SW1A 1ER 

United Kingdom 
 Fax: +44 (0) 20 7170 1099

 Attn: Jonathan Biggs 
 Attn: Harry
Nelis 
 Norwest Venture Partners VII-A LP 
 Norwest Venture Partners X, LP 
 525 University Avenue 

Palo Alto, Ca. 94301 
 650.321.8000 

Lehman Brothers Venture Partners V L.P. 
 Lehman
Brothers Venture Partners V-P, L.P. 
 LB I Group, Inc. 
 3000 Sand Hill Road, Building 3, Suite 190 
 Menlo Park, California 94025-7103 

Trident Capital Fund-V, L.P 
 Trident Capital
Fund-V Affiliates Fund, L.P. 
 Trident Capital Fund-V Affiliates Fund (Q), L.P. 
 Trident Capital Fund-V Principals Fund, L.P. 
 Trident Capital Parallel Fund-V, C.V. 

505 Hamilton Ave, Suite 200 
 Palo Alto, CA 94301

  
 Gold Hill Venture Lending 03, L.P.

 Two Newton Executive Park, Suite 203 

Newton, MA 02462 

  
 Holders: 

Daniel Stephen Hafner 
 2347 Bronson Road

 Fairfield, CT 06824 
 Fax:
(203) 899-3125 
 Paul English 

10 Samoset Road 
 Winchester, MA 01890

 America Online, Inc. 
 22000 AOL Way

 Dulles, VA 20166 
 Attn: Deputy
General Counsel 
 Fax: (703) 265-1105 
 McKane 2007 Grandchildren Trust 
 48 Owenoke Park 

Westport, CT 06880 
 J.M. Hafner Trust

 6 Longfellow Lane 
 Houston, TX 77005

 Joseph A. Hafner Trust 
 1316 Peq l
uot Avenue 
 Southport, CT 06890 

Merrill T. Hafner Trust 
 1316 Pequot Avenue

 Southport, CT 06890 
 Paul M.
English and Jean A English, as trustees of The Paul M. English 2007 Irrevocable Family Trust 
 10 Samoset Road 

Winchester, MA 01890 
 Paul M. English and Jean
A English, as trustees of The Paul M. English 2006 Irrevocable Family Trust 
 10 Samoset Road 

Winchester, MA 01890 
 D.S. Hafner Trust

 1316 Pequot Avenue 
 Southport, CT
06890 

  
 SCHEDULE II

 KAYAK SOFTWARE CORPORATION 
 INSTRUMENT OF ACCESSION 
 The undersigned,
                                         
   , as a condition precedent to becoming the owner or holder of record of
                                         
                       ) shares of the
                                     stock, par value $.001
per share, of Kayak Software Corporation, a Delaware corporation (the “Company”), or options to purchase such stock, hereby agrees to become a [Holder/Investor] under that certain Fifth Amended and Restated Stock
Restriction and Co-Sale Agreement dated as of December —, 2007 by and among the Company and other stockholders of the Company party thereto. This Instrument of Accession shall take effect and shall become an integral part of, and the
undersigned shall become a party to and bound by, said Fourth Amended and Restated Stock Restriction and Co-Sale Agreement immediately upon execution and delivery to the Company of this Instrument of Accession. 

IN WITNESS WHEREOF, this INSTRUMENT OF ACCESSION has been duly executed by or on behalf of the undersigned, as of the date below written. 

 

			
	 Signature:
  

	(Print Name)	 	  

		
	Address:	 	
	  

	
 

			
	Date:	 	  

 

			
	Accepted:
	
	KAYAK SOFTWARE CORPORATION
		
	By:	 	  

			
	     Name:	 	
	     Title:	 	

			
	Date:

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00181-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00181-of-00352.parquet"}]]